[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1801
1. Ruiz-Molina JM, Ochoa-Sánchez EP, López-Basave HN, Barrera-Franco JL, Crocifoglio-Vincenzo A, Medina-Castro JM: [Open splenectomy: ten-year experience in an oncological referral center]. Cir Cir; 2007 May-Jun;75(3):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During an average 81-month follow-up we found 14 patients (56%) asymptomatic, two patients (8%) with documented tumoral activity (angiosarcoma and non-Hodgkin's lymphoma) and one patient (4%) developed a second neoplasm.
  • Six patients (24%) died due to underlying disease (chronic myeloid leukemia and lymphoma), one patient (4%) with active disease (Hodgkin's disease) and one patient (4%) died due to other causes.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Referral and Consultation. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659166.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


2. Rödel S, Engert A, Diehl V, Reiser M: Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study. Leuk Lymphoma; 2005 Dec;46(12):1729-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study.
  • The aim of the present study was to evaluate the feasibility and efficacy of the intensified induction chemotherapy regimen ACOMED for patients with aggressive non-Hodgkin's lymphoma (NHL).
  • Untreated adult patients with aggressive NHL, presenting with Ann Arbour stage II-IV disease or stage I with bulky disease, and with at least one of the following risk factors: age > 60 years, advanced disease, elevated serum lactate dehydrogenase level, Eastern Cooperative Oncology Group (ECOG) performance status >or= 2, presence of extranodal sites of disease and bulky disease, were treated with the ACOMED regimen consisting of 4-6 cycles of adriamycin 25 mg/m(2) i.v. on days 4-5, cyclophosphamide 250 mg/m(2) i.v. on days 1-5, vincristine 2 mg i.v. absolute on day 1, methotrexate 500 mg/m(2) i.v. on day 1 with leucovorin-rescue after 24 h 30 mg/m(2) i.v. and 3 x 15 mg p.o., etoposide 100 mg/m(2) i.v. on days 3-5, dexamethasone 10 mg/m(2) p.o. on days 1-5 and granulocyte colony-stimulating factor support, repeated on day 21.
  • ACOMED followed by involved field radiation presents a highly effective regimen for remission induction and long-term survival in patients with aggressive NHL, and merits further investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Radiotherapy / adverse effects. Survival Analysis. Survivors. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353313.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. Chebotkevich VN, Bessmel'tsev SS, Volkov AV, Shilova ER: [Molecular biology investigation of respiratory viruses as a factor of infectious complications in hemoblastosis and myelodepression]. Vopr Onkol; 2006;52(4):421-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Communicable respiratory viruses as a causative factor of infectious complication in hemoblastosis and myelodepression were investigated in 51 patients (aplastic anemia--3, multiple myeloma--10, different patterns of acute leukemia--16, chronic leukemia--8 and non-Hodgkin's lymphoma--14).
  • [MeSH-major] Anemia, Aplastic / complications. Leukemia / complications. Lymphoma, Non-Hodgkin / complications. Multiple Myeloma / complications. Respiratory Tract Infections / virology. Virus Diseases / virology
  • [MeSH-minor] Adenoviridae / isolation & purification. Adolescent. Adult. Aged. Coronavirus / isolation & purification. Female. Humans. Influenza A virus / isolation & purification. Influenza B virus / isolation & purification. Male. Middle Aged. Polymerase Chain Reaction. Respiratory Syncytial Viruses / isolation & purification


Advertisement
4. Marshall NA, Culligan DJ, Tighe J, Johnston PW, Barker RN, Vickers MA: The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol; 2007 Apr;35(4):596-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma.
  • OBJECTIVE: Epstein-Barr virus (EBV) encoded latent membrane protein 1 (LMP1) is expressed by the malignant cells of about 30% of cases of Hodgkin's lymphoma (HL) and is therefore a potential target for immune attack.
  • [MeSH-major] Hodgkin Disease / physiopathology. T-Lymphocytes, Regulatory / immunology. Viral Matrix Proteins / physiology
  • [MeSH-minor] Adult. Cell Proliferation. Cytokines / metabolism. Female. Herpesvirus 4, Human / isolation & purification. Humans. Male. Middle Aged


5. Ho CL, Hsieh AT, Dai MS, Chen YC, Kao WY, Chao TY: Non-Hodgkin's lymphoma of the stomach: treatment outcomes for 57 patients over a 20-year period. J Chin Med Assoc; 2005 Jan;68(1):11-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the stomach: treatment outcomes for 57 patients over a 20-year period.
  • BACKGROUND: Gastric non-Hodgkin's lymphoma (NHL) is a rare subtype of malignancy, for which no consensus exists about treatment.
  • In this study, the treatment outcomes of gastric NHL in 57 patients were retrospectively evaluated for a period of 20 years at a single institute.
  • The 46 stage I/II patients received aggressive, multimodal therapy: 24 of these (group A) were treated with surgery-based management, which included surgery alone (n = 6), surgery + chemotherapy (CT; n = 14), surgery + radiotherapy (RT; n = 2), and surgery + CT + RT (n = 2); 22 patients (group B) did not receive surgery, but received CT alone (n = 11), CT + RT (n = 5), or, in patients with low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, an oral anti-Helicobacter pylori regimen (n = 6).
  • RESULTS: Except for 1 patient with an initial surgical diagnosis, 56 patients underwent gastric endoscopic examination, which proved that 42 had NHL.
  • Of the 22 non-surgical patients (group B) who received CT, alone or combined with RT, 14 remained disease-free after a median follow-up of 40 months (range, 4-189 months); 1 patient died because of massive gastric hemorrhage after CT.
  • CONCLUSION: Clinical stage is the most important factor predicting the long-term survival of patients with gastric NHL.
  • In early-stage gastric NHL, non-surgical treatment seems able to achieve the aims of improved long-term survival and, in some instances, cure.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Stomach / pathology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742857.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


6. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, Van Hoof A, Tilly H, Gaulard P, Coiffier B, Gisselbrecht C, Brousse N, Reyes F, Hermine O, Groupe d'Etude des Lymphomes de l'Adulte Programs: Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol; 2006 Feb 20;24(6):953-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
  • PURPOSE: Epidemiologic studies show an association between hepatitis C virus (HCV) and B-cell non-Hodgkin's lymphoma (NHL).
  • Treatment and outcome of patients with diffuse large-cell lymphoma (DLCL) and HCV infection are still a matter of debate.
  • RESULTS: Histologic types of HCV-positive DLCL were more frequently transformed from low-grade lymphoma than DLCL in HCV-negative patients (32% v 6%, P = .02).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatitis C / complications. Hepatitis C Antigens / blood. Liver / drug effects. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Aged. Antiviral Agents / therapeutic use. Disease-Free Survival. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Seroepidemiologic Studies. Severity of Illness Index. Spleen / pathology. Spleen / virology. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Jul 20;24(21):3513; author reply 3513-4 [16849775.001]
  • (PMID = 16418500.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis C Antigens
  •  go-up   go-down


7. Simon Z, Keresztes K, Miltényi Z, Ress Z, Váróczy L, Vadász G, Gergely L, Illés A: [Our experiences in treating patients with Hodgkin disease in the last decade]. Orv Hetil; 2007 Apr 15;148(15):675-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Our experiences in treating patients with Hodgkin disease in the last decade].
  • [Transliterated title] Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben.
  • INTRODUCTION: Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred.
  • AIM: To summarize the clinical and histological data of patients with Hodgkin's disease, treated at the 3rd Department of Internal Medicine, University of Debrecen between 1995-2004.
  • RESULTS: The mean age of the 163 patients at the diagnosis was 36 years (14-75), with bimodal age distribution, the most frequent disease subtype was mixed-cell Hodgkin's disease (48.5%).
  • 10 patients with partial remission and 5 non-responders were continually treated.
  • During the follow-up 18 patients died, 11 due to the lymphoma progression, or as the result of treatment, 6 had secondary malignancies, 1 due to other reasons.
  • CONCLUSION: The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) aggressive primary treatment should be used even with more severe side effects and complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Hungary. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416575.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; COPP protocol; MOPP protocol
  •  go-up   go-down


8. Glasheen JJ, Sorensen MD: Burkitt's lymphoma presenting with lactic acidosis and hypoglycemia - a case presentation. Leuk Lymphoma; 2005 Feb;46(2):281-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma presenting with lactic acidosis and hypoglycemia - a case presentation.
  • We present what appears to be the first reported case of lactic acidosis and hypoglycemia in an adult patient with Burkitt's lymphoma.
  • Lactic acidosis and hypoglycemia are rare complications of non-Hodgkin's lymphoma (NHL) with only 26 and 8 previous reports, respectively.
  • Two prior cases of Burkitt's lymphoma-induced lactic acidosis have been reported (one child, one adult), both in the absence of hypoglycemia.
  • Thoracentesis and bone marrow studies revealed Burkitt's lymphoma.
  • An extensive review of the literature demonstrates that NHL-induced lactic acidosis is associated with a mortality rate of 73% at 1 month and 92% overall with the clinical course closely linked to the chemotherapeutic response of the tumor.
  • [MeSH-major] Acidosis, Lactic / etiology. Burkitt Lymphoma / complications. Hypoglycemia / etiology


9. Cervetti G, Mechelli S, Riccioni R, Galimberti S, Caracciolo F, Petrini M: High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clin Exp Rheumatol; 2005 Nov-Dec;23(6):877-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The evidence of an increased frequency of B-non Hodgkin's lymphomas (NHL) in patients with HCV and systemic autoimmune diseases suggests a close relationship between infection, autoimmunity and cancer.
  • Choosing the best therapy for patients affected either by HCV-related lymphoma or autoimmune disorders is not easy; in fact, some treatments may be accompanied by an excessive hepatic toxicity and may be followed by a reactivation of hepatitis.
  • RESULTS: In this paper we evaluate the role of anti-CD20 monoclonal antibody in mono-therapy in 10 patients with either indolent HCV-related lymphoma or autoimmune disease.
  • A very high rate of response, of both NHL and of the associated autoimmune disease, was observed (100% of clinical response), with no significant hepatic and extra-hepatic toxicity.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Autoimmune Diseases / drug therapy. Hepatitis C, Chronic / complications. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396708.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


10. Kestler MH, Gardner EM, Cohn DL: Hepatic non-Hodgkin's lymphoma with lactic acidosis in HIV-infected patients: report of 2 cases. J Int Assoc Physicians AIDS Care (Chic); 2010 Sep-Oct;9(5):301-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic non-Hodgkin's lymphoma with lactic acidosis in HIV-infected patients: report of 2 cases.
  • We report 2 patients with HIV-associated non-Hodgkin's lymphoma with massive hepatic involvement and lactic acidosis.
  • [MeSH-major] Acidosis, Lactic / etiology. Liver Neoplasms / complications. Lymphoma, AIDS-Related / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Humans. Male. Middle Aged. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Lactic Acidosis.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20739590.001).
  • [ISSN] 1545-1097
  • [Journal-full-title] Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)
  • [ISO-abbreviation] J Int Assoc Physicians AIDS Care (Chic)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


11. Karanikiotis C, Daniilidis M, Karyotis N, Bakogiannis C, Economopoulos T, Murray S, Papamichael D, Samantas E, Nikolaou A, Skoura L, Tselis N, Zamboglou N, Fountzilas G: HLA Class II alleles and the presence of circulating Epstein-Barr virus DNA in Greek patients with nasopharyngeal carcinoma. Strahlenther Onkol; 2008 Jun;184(6):325-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EBV-DNA detection was also applied in 66 patients with EBV-related malignancies (Hodgkin's [HL] and non-Hodgkin's lymphoma [NHL]) and infectious mononucleosis (IM), as well as in 80 healthy EBV-seropositive controls.
  • RESULTS: 81% of the NPC patients, 77.8% with HL, 72.2% with NHL, and 66.7% with IM were EBV-DNA positive, whereas the EBV genome was detected only in 15% of the healthy controls.
  • [MeSH-minor] Adult. Female. Gene Frequency / genetics. Genetic Predisposition to Disease / genetics. Genetics, Population. Greece. HLA-DQ alpha-Chains. HLA-DQ beta-Chains. HLA-DRB1 Chains. Humans. Male

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18535809.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / HLA-DQ Antigens; 0 / HLA-DQ alpha-Chains; 0 / HLA-DQ beta-Chains; 0 / HLA-DQA1 antigen; 0 / HLA-DQB1 antigen; 0 / HLA-DR Antigens; 0 / HLA-DRB1 Chains
  •  go-up   go-down


12. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vokurka S, Quinn B, McCann S, European Blood and Marrow Transplantation Mucositis Advisory Group: Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol; 2008 Mar 20;26(9):1519-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The Prospective Oral Mucositis Audit assessed the incidence, duration, and determinants of severe oral mucositis (OM; WHO oral toxicity scale grades 3 to 4) in patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) receiving high-dose conditioning chemotherapy before autologous stem-cell transplantation.
  • PATIENTS AND METHODS: Patients with MM (n = 109; mean age, 57 +/- 8 years) or NHL (n = 88; mean age, 50 +/- 13 years) were treated with high-dose melphalan (200 mg/m(2)) or carmustine 300 mg/m(2), etoposide 800 mg/m(2), cytarabine 800 to 1,600 mg/m(2), and melphalan 140 mg/m(2) chemotherapy, respectively, in 25 European centers.
  • RESULTS: Severe OM occurred in 46% (95% CI, 36% to 56%) of patients with MM and 42% (95% CI, 32% to 53%) of patients with NHL, with a mean duration of 5.3 days (95% CI, 4.4 to 6.1 days) and 5.5 days (95% CI, 4.5 to 6.7 days), respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy. Multiple Myeloma / therapy. Stomatitis / chemically induced. Stomatitis / epidemiology. Transplantation Conditioning / adverse effects
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Carmustine / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Etoposide / adverse effects. Europe / epidemiology. Female. Humans. Incidence. Male. Medical Audit. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Myeloablative Agonists / administration & dosage. Myeloablative Agonists / adverse effects. Prospective Studies. Research Design. Risk Assessment. Risk Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268357.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  • [Investigator] Ferrant A; Harousseau JL; Villalobos M; Eggers; Kienast J; Mico C; Isidori A; Curti A; Mele G; Meloni G; Span B; Valcarcel D; Martinez C; Perez S; Ljungman P; Theocharides A; Drake M; Russell N; Morgan G
  •  go-up   go-down


13. Blayney DW, McGuire BW, Cruickshank SE, Johnson DH: Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. Oncologist; 2005 Feb;10(2):138-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
  • We conducted two phase I studies, in non-small cell lung cancer (NSCLC) and in lymphoma, to explore the possibility of intensifying chemotherapy by compressing the delivery of and escalating the dose of standard combination chemotherapy.
  • The second study used cyclophosphamide, doxorubicin, vincristine, and prednisone, CHOP chemotherapy, in the treatment of stage II-IV intermediate or immunoblastic high-grade lymphoma, intensifying chemotherapy first by reducing the cycle length and then by escalating the dosages of cyclophosphamide and doxorubicin.
  • Fifty-five patients with NSCLC and 49 with non-Hodgkin's lymphoma (NHL) were enrolled and treated in successive cohorts.
  • In the NSCLC trial, etoposide and cisplatin were intensified by >50%, and in the lymphoma trial, cyclophosphamide was intensified by 270% and doxorubicin was intensified by 87%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Recombinant Proteins. Thrombocytopenia / chemically induced. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709216.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone
  •  go-up   go-down


14. Frobisher C, Lancashire ER, Reulen RC, Winter DL, Stevens MC, Hawkins MM, British Childhood Cancer Survivor Study: Extent of alcohol consumption among adult survivors of childhood cancer: the British Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1174-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of alcohol consumption among adult survivors of childhood cancer: the British Childhood Cancer Survivor Study.
  • However, survivors of Hodgkin's lymphoma, non-Hodgkin's lymphoma, Wilms' tumor, bone sarcoma, and soft tissue sarcoma had adverse drinking behaviors at levels expected from the general population.
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Risk Factors. Surveys and Questionnaires. Young Adult

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • (PMID = 20447915.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Easton D; Hawkins M; Jenkinson H; Jenney M; Lancashire E; Pritchard-Jones K; Stevens M; Stiller C; Sugden E; Toogood A; Wallace H
  •  go-up   go-down


15. Das DK, Francis IM, Sharma PN, Sathar SA, John B, George SS, Mallik MK, Sheikh ZA, Haji BE, Pathan SK, Madda JP, Mirza K, Ahmed MS, Junaid TA: Hodgkin's lymphoma: diagnostic difficulties in fine-needle aspiration cytology. Diagn Cytopathol; 2009 Aug;37(8):564-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma: diagnostic difficulties in fine-needle aspiration cytology.
  • It is commonly believed that cytodiagnosis of Hodgkin's lymphoma (HL) is much easier than that of non-Hodgkin lymphoma (NHL).
  • However, recognition of certain NHL subtypes with Reed-Sternberg (R-S)-like cells and results of immunohistochemical studies point to the contrary.
  • To study the limitations of cytology in diagnosis of HL, fine-needle aspiration (FNA) smears of 130 lymphoma or suspected lymphoma cases were reviewed.
  • Among histologically diagnosed HL cases, definitive cytodiagnosis of HL (initial as well as reviewed) was significantly less frequent than cytodiagnosis of NHL among histologically diagnosed NHL cases (P = 0.0328 and = 0.0001, respectively).
  • On the other hand, cytologically diagnosed HL/NHL cases were significantly more frequent in the former group (P = 0.0001 and = 0.0018, respectively).
  • ALCL and TCRBCL were the two NHL subtypes which created confusion with HL in FNA smears.
  • Hodgkin/Hodgkin-like cells and typical R-S cells were significantly more frequent in FNA smears of the concordant group (P = 0.0478 and = 0.0431, respectively).
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19373880.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Dong P, Wang B, Sun QY, Cui H: Tuberculosis versus non-Hodgkin's lymphomas involving small bowel mesentery: evaluation with contrast-enhanced computed tomography. World J Gastroenterol; 2008 Jun 28;14(24):3914-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculosis versus non-Hodgkin's lymphomas involving small bowel mesentery: evaluation with contrast-enhanced computed tomography.
  • METHODS: We retrospectively reviewed the anatomic distribution, CT enhancement patterns of lymphoma in 18 patients with mesenteric tuberculosis and 22 with untreated non-Hodgkin's lymphomas (NHL) involving small bowel mesentery (SBM).
  • RESULTS: CT showed that tuberculosis and NHL mainly affected lymph nodes in the body and root of SBM.
  • Homogeneously enhanced lymph nodes in the body and root of SBM were found more often in the NHL (P < 0.05).
  • "Sandwich sign" in the root of SBM was observed more often in NHL (P < 0.05).
  • CONCLUSION: Anatomic lymph node distribution, sandwich sign and specific enhancement patterns of lymphadenopathy in SBM on CT images can be used in differentiating between tuberculosis and untreated NHL involving SBM.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiography. Mesentery / radiography. Peritoneal Diseases / radiography. Tomography, X-Ray Computed / methods. Tuberculosis, Lymph Node / radiography
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Lymph Nodes / radiography. Lymphatic Diseases / radiography. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1988 Mar;83(3):301-3 [3344733.001]
  • [Cites] AJR Am J Roentgenol. 1987 Sep;149(3):575-81 [3497547.001]
  • [Cites] AJR Am J Roentgenol. 1990 Aug;155(2):267-70 [2115249.001]
  • [Cites] Abdom Imaging. 1993;18(2):109-16 [8439748.001]
  • [Cites] Crit Rev Microbiol. 1993;19(1):1-16 [8481210.001]
  • [Cites] J Comput Assist Tomogr. 1994 Jan-Feb;18(1):59-62 [8282885.001]
  • [Cites] JAMA. 1995 Jan 18;273(3):220-6 [7807661.001]
  • [Cites] Radiol Clin North Am. 1995 Jul;33(4):691-705 [7610239.001]
  • [Cites] Radiol Clin North Am. 1995 Jul;33(4):707-17 [7610240.001]
  • [Cites] Diagn Microbiol Infect Dis. 1995 Nov;23(3):111-3 [8849655.001]
  • [Cites] Radiology. 1997 Feb;202(2):367-72 [9015059.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1455-60 [9168707.001]
  • [Cites] Eur Radiol. 1998;8(6):886-900 [9683690.001]
  • [Cites] AJR Am J Roentgenol. 1999 Mar;172(3):619-23 [10063847.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jan;184(1):41-4 [15615948.001]
  • [Cites] Radiographics. 2005 Mar-Apr;25(2):351-65 [15798054.001]
  • [Cites] World J Gastroenterol. 2008 Apr 14;14(14):2284-7 [18407612.001]
  • [Cites] JAMA. 1994 Aug 17;272(7):535-9 [8046808.001]
  • [Cites] Radiographics. 2001 Nov-Dec;21(6):1475-90 [11706218.001]
  • [Cites] Int J Colorectal Dis. 2002 May;17(3):192-8 [12049314.001]
  • [Cites] Br J Radiol. 2003 Jan;76(901):22-5 [12595321.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23(2):457-73; quiz 535-6 [12640160.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1361-4 [12800257.001]
  • [Cites] Radiology. 1980 Feb;134(2):467-73 [7352232.001]
  • [Cites] J Comput Assist Tomogr. 1982 Jun;6(3):490-6 [7096694.001]
  • [Cites] AJR Am J Roentgenol. 1982 Nov;139(5):861-6 [6981966.001]
  • [Cites] J Comput Assist Tomogr. 1982 Dec;6(6):1127-37 [7174930.001]
  • [Cites] Radiology. 1983 Oct;149(1):219-24 [6611928.001]
  • [Cites] Radiology. 1985 Oct;157(1):199-204 [4034967.001]
  • [Cites] J Comput Assist Tomogr. 1989 May-Jun;13(3):433-6 [2723174.001]
  • (PMID = 18609719.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2721452
  •  go-up   go-down


17. Faustini A, Colais P, Fabrizi E, Bargagli AM, Davoli M, Di Lallo D, Di Napoli A, Pezzotti P, Sorge C, Grillo R, Maresca C, Recchia O, Perucci CA, HCV laboratory surveillance Lazio-Region Group: Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups. BMC Infect Dis; 2010;10:97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cirrhosis, hepatocellular carcinoma and encephalopathy were the most frequent hepatic sequelae; cryoglobulinaemia and non-Hodgkin's lymphoma were the most frequent extrahepatic sequelae.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / epidemiology. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Italy / epidemiology. Liver Cirrhosis / epidemiology. Liver Neoplasms / epidemiology. Male. Middle Aged. Neurotoxicity Syndromes / epidemiology. Prevalence. Renal Dialysis / adverse effects. Sex Factors. Substance-Related Disorders / complications. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1999 Jun;44(6):874-80 [10323892.001]
  • [Cites] Rev Soc Bras Med Trop. 2009 May-Jun;42(3):239-44 [19684968.001]
  • [Cites] N Engl J Med. 2001 Jul 5;345(1):41-52 [11439948.001]
  • [Cites] J Hepatol. 2001 Aug;35(2):284-9 [11580153.001]
  • [Cites] Am J Kidney Dis. 2001 May;37(5):1004-10 [11325683.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3138-41 [11721761.001]
  • [Cites] BMJ. 2002 Feb 23;324(7335):450-3 [11859045.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4588-91 [12036892.001]
  • [Cites] Blood. 2003 Aug 1;102(3):996-9 [12714514.001]
  • [Cites] J Pediatr. 2003 Jul;143(1):54-9 [12915824.001]
  • [Cites] Int J Epidemiol. 2003 Oct;32(5):717-24 [14559738.001]
  • [Cites] Lancet. 2003 Dec 20;362(9401):2095-100 [14697814.001]
  • [Cites] NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46 [14768714.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1618-24 [14576071.001]
  • [Cites] JAMA. 1996 Nov 20;276(19):1563-7 [8918853.001]
  • [Cites] N Engl J Med. 1997 Jul 24;337(4):237-40 [9227929.001]
  • [Cites] Lancet. 1998 Jan 31;351(9099):351-5 [9652633.001]
  • [Cites] BMJ. 1998 Aug 15;317(7156):433-7 [9703523.001]
  • [Cites] J Rheumatol. 1999 Feb;26(2):370-2 [9972971.001]
  • [Cites] Minerva Urol Nefrol. 2005 Sep;57(3):175-97 [15986016.001]
  • [Cites] Lancet Infect Dis. 2005 Sep;5(9):558-67 [16122679.001]
  • [Cites] Infect Control Hosp Epidemiol. 2005 Sep;26(9):762-7 [16209382.001]
  • [Cites] J Med Virol. 2005 Dec;77(4):509-18 [16254983.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):705-14 [16702586.001]
  • [Cites] Am J Kidney Dis. 2006 Oct;48(4):629-37 [16997059.001]
  • [Cites] World J Gastroenterol. 2007 May 7;13(17):2436-41 [17552026.001]
  • [Cites] World J Gastroenterol. 2007 May 7;13(17):2467-78 [17552031.001]
  • [Cites] Int J Epidemiol. 2007 Aug;36(4):731-7 [17693458.001]
  • [Cites] J Hepatol. 2008 Jan;48(1):148-62 [18022726.001]
  • [Cites] J Viral Hepat. 2008 Jul;15(7):538-50 [18397223.001]
  • [Cites] Biostatistics. 2008 Oct;9(4):715-34 [18349037.001]
  • [Cites] Cent Eur J Public Health. 2008 Sep;16(3):106-10 [18935772.001]
  • [Cites] J Clin Virol. 2009 Mar;44(3):200-6 [19195927.001]
  • [Cites] BMC Public Health. 2009;9:34 [19161623.001]
  • [Cites] J Med Virol. 2009 May;81(5):836-43 [19319981.001]
  • [Cites] World J Gastroenterol. 2009 Apr 7;15(13):1537-47 [19340895.001]
  • [Cites] Clin Nephrol. 2009 Apr;71(4):423-9 [19356375.001]
  • [Cites] N Engl J Med. 1999 Aug 19;341(8):556-62 [10451460.001]
  • (PMID = 20403169.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2867994
  •  go-up   go-down


18. Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, Hall P, Langmark F, Pukkala E, Andersson M, Kaijser M, Joensuu H, Fosså SD, Travis LB: Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol; 2007 Apr 20;25(12):1489-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma.
  • PURPOSE: Hodgkin's lymphoma (HL) survivors are known to be at substantially increased risk of solid cancers (SC).
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / pathology. Survivors / statistics & numerical data
  • [MeSH-minor] Adult. Age Distribution. Disease-Free Survival. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Poisson Distribution. Probability. Registries. Retrospective Studies. Risk Assessment. Severity of Illness Index. Sex Distribution. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372278.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, Feng FY: [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Ai Zheng; 2005 Apr;24(4):465-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
  • BACKGROUND & OBJECTIVE: So far, there is still no standard salvage regimen for relapsed or refractory non-Hodgkin's lymphoma (NHL).
  • The response rates (RR) of NHL patients received common salvage regimens, such as DICE, ESHAP, MINE, and EPOCH, are only 30%-70%.
  • This study was to evaluate the efficacy and safety of DICE regimen, as a salvage regimen, in treating patients with relapsed or refractory intermediate and high grade NHL.
  • METHODS: Thirty-five patients with relapsed or refractory intermediate and high grade NHL, who had been pretreated with chemotherapy dominated by CHOP or CHOP-like regimen with a median of 6 cycles (ranged 2-12 cycles), were salvaged by DICE regimen from Jun.
  • The RRs of T-cell and B-cell NHL were 85.7% and 66.7%.
  • The CR rate was higher in T-cells NHL than in B-cell NHL (50.0% vs. 19.0%, P=0.073).
  • The response to DICE reginmen was an independent prognostic factor of patients with relapsed or refractory NHL (P = 0.001).
  • CONCLUSIONS: DICE regimen is a safe and effective salvage regimen for the patients with relapsed or refractory intermediate and high grade advanced NHL.
  • The response to DICE regimen may directly influence survival time of patients with relapsed or refractory NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Recurrence, Local. Neutropenia / chemically induced. Remission Induction. Survival Rate. Thrombocytopenia / chemically induced. Transplantation, Autologous

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820071.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EC 1.1.1.27 / L-Lactate Dehydrogenase; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; DICE protocol
  •  go-up   go-down


20. Vo TT, Gladen BC, Cooper GS, Baird DD, Daniels JL, Gammon MD, Richardson DB: Dichlorodiphenyldichloroethane and polychlorinated biphenyls: intraindividual changes, correlations, and predictors in healthy women from the southeastern United States. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2729-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dichlorodiphenyldichloroethane (DDE) and polychlorinated biphenyls (PCB) are widespread environmental contaminants that have been postulated to increase the risk of diseases such as non-Hodgkin's lymphoma, breast cancer, as well as lead to early menopause.
  • [MeSH-minor] Adult. Body Mass Index. Female. Humans. Interviews as Topic. Linear Models. Predictive Value of Tests. Pregnancy. Southeastern United States / epidemiology. Surveys and Questionnaires. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DDD .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chemosphere. 2006 Feb;62(7):1167-82 [16169054.001]
  • [Cites] Arch Environ Contam Toxicol. 1989 Jul-Aug;18(4):495-500 [2505694.001]
  • [Cites] Chemosphere. 2007 Jun;68(5):824-31 [17408721.001]
  • [Cites] Epidemiology. 2002 Nov;13(6):729-33 [12410018.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):271-7 [10750665.001]
  • [Cites] Environ Res. 2006 Jul;101(3):387-94 [16352301.001]
  • [Cites] Vital Health Stat 11. 1993 Mar;(242):1-107 [7682373.001]
  • [Cites] Am J Epidemiol. 1996 Feb 1;143(3):228-39 [8561156.001]
  • [Cites] Int J Epidemiol. 1999 Apr;28(2):179-88 [10342677.001]
  • [Cites] Crit Rev Clin Lab Sci. 1997;34(1):67-139 [9055057.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2224-36 [16172236.001]
  • [Cites] Cancer Causes Control. 2000 Feb;11(2):177-84 [10710203.001]
  • [Cites] Chemosphere. 2006 Jul;64(4):642-9 [16375948.001]
  • [Cites] Vital Health Stat 11. 1986 May;(236):1-59 [3750882.001]
  • [Cites] Eur J Cancer Prev. 2003 Dec;12(6):509-16 [14639129.001]
  • [Cites] Environ Res. 2001 Jun;86(2):128-39 [11437459.001]
  • [Cites] Arch Environ Contam Toxicol. 1992 May;22(4):362-6 [1489385.001]
  • [Cites] Nature. 1972 Jul 28;238(5361):221-3 [4558351.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1179-85 [16882522.001]
  • [Cites] Annu Rev Public Health. 1997;18:211-44 [9143718.001]
  • [Cites] Environ Health Perspect. 2003 May;111(5):702-7 [12727597.001]
  • [Cites] Environ Health Perspect. 1995 Oct;103 Suppl 7:141-5 [8593861.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5545-52 [17545638.001]
  • [Cites] J Pediatr. 2000 May;136(5):599-605 [10802490.001]
  • [Cites] Environ Health Perspect. 2007 Oct;115(10):1406-14 [17938728.001]
  • [Cites] J Toxicol Environ Health A. 2004 Sep 24;67(18):1407-22 [15371229.001]
  • [Cites] Br J Ind Med. 1992 Jul;49(7):527-8 [1637716.001]
  • [Cites] Sci Total Environ. 2006 Dec 15;372(1):20-31 [16650462.001]
  • [Cites] Environ Sci Technol. 2001 Feb 1;35(3):435-40 [11351711.001]
  • [Cites] J Assoc Off Anal Chem. 1984 Jan-Feb;67(1):122-9 [6321428.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):373-6 [17337641.001]
  • [Cites] Chemosphere. 2006 Aug;64(9):1507-13 [16466768.001]
  • [Cites] Environ Res. 1992 Oct;59(1):202-16 [1425510.001]
  • [Cites] Environ Pollut. 2000 Nov;110(2):253-65 [15092840.001]
  • [Cites] Bull Environ Contam Toxicol. 1987 Jan;38(1):117-24 [2434165.001]
  • [Cites] Chemosphere. 2000 May-Jun;40(9-11):1111-23 [10739053.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):193-7 [10698481.001]
  • [Cites] Am J Obstet Gynecol. 1982 Jul 15;143(6):626-37 [7091235.001]
  • [Cites] Int J Obes Relat Metab Disord. 2001 Nov;25(11):1585-91 [11753575.001]
  • [Cites] Arch Environ Health. 1989 Nov-Dec;44(6):351-4 [2514628.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1999 Apr-Jun;2(2):183-210 [10230393.001]
  • [Cites] Environ Health Perspect. 1998 Feb;106 Suppl 1:171-89 [9539012.001]
  • [Cites] Int J Clin Pharmacol Ther. 1999 Jan;37(1):8-19 [10027478.001]
  • [Cites] Sci Total Environ. 1996 Sep 9;187(3):199-210 [8711465.001]
  • [Cites] Am J Epidemiol. 1998 Mar 1;147(5):493-502 [9525537.001]
  • [Cites] Am J Public Health. 1986 Feb;76(2):172-7 [3080910.001]
  • [Cites] Epidemiology. 2000 May;11(3):249-54 [10784239.001]
  • [Cites] Sci Total Environ. 1997 Nov 14;207 (1):55-61 [9397600.001]
  • (PMID = 18843016.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA ES049003-20; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; DFC2HB4I0K / Polychlorinated Biphenyls; V14159DF29 / Dichlorodiphenyldichloroethane
  •  go-up   go-down


21. Björkholm M, Celsing F, Johansson E, Swedish Lymphoma Study Group: Sequential multidrug chemotherapy (CHOP-VA-MB) in patients with high-grade non-Hodgkin's lymphoma--a 20-year follow-up. Ann Hematol; 2006 Oct;85(10):731-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential multidrug chemotherapy (CHOP-VA-MB) in patients with high-grade non-Hodgkin's lymphoma--a 20-year follow-up.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Male. Mechlorethamine / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Time Factors. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Hematol. 2005 Apr;84(4):217-22 [15538568.001]
  • (PMID = 16838163.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; CHOP-B protocol; M-BACOD protocol; ProMACE-MOPP protocol
  •  go-up   go-down


22. Schaefer NG, Strobel K, Taverna C, Hany TF: Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging; 2007 Jan;34(1):60-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone involvement in patients with lymphoma: the role of FDG-PET/CT.
  • PURPOSE: To evaluate the diagnostic impact and clinical significance of FDG-avid bone lesions detected by FDG-PET/CT in patients with lymphoma.
  • METHODS: The study population comprised 50 consecutive patients (mean age 41.7+/-15.5 years; 27 female, 23 male; 41 staging, 9 restaging) with Hodgkin's disease (n=22) or aggressive non-Hodgkin's lymphoma (n=28) in whom FDG-avid bone lesions were detected by FDG-PET/CT.
  • Additional PET/CT information regarding uni- or multifocal bone involvement resulted in lymphoma upstaging in 21 (42%) patients compared with the combined information provided by CT and BMB.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Fluorodeoxyglucose F18. Image Enhancement / methods. Lymphoma / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Subtraction Technique

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1163-72 [1694234.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1018-27 [12163626.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 1:i58-9 [15888757.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):958-63 [15937306.001]
  • [Cites] Radiology. 2005 Nov;237(2):627-34 [16244271.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 1:i54-5 [15888755.001]
  • [Cites] Eur J Haematol. 1987 Jul;39(1):66-70 [3653373.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):888-97 [6977408.001]
  • [Cites] Eur Radiol. 2004 Oct;14 (10 ):1829-41 [15365752.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):603-9 [9469348.001]
  • [Cites] Clin Nucl Med. 2005 Feb;30(2):131-4 [15647689.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):403-9 [7844601.001]
  • [Cites] J Nucl Med. 1999 Sep;40(9):1407-13 [10492357.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1522-31 [11920510.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1401-2 [15870088.001]
  • [Cites] Radiology. 2001 Dec;221(3):818-21 [11719684.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):210-2 [7819042.001]
  • [Cites] Recent Results Cancer Res. 2000;156:78-89 [10802866.001]
  • [Cites] Radiology. 1986 Oct;161(1):191-4 [3763865.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jan;184(1):185-92 [15615972.001]
  • [Cites] Blood. 1998 May 1;91(9):3340-6 [9558391.001]
  • [Cites] Eur J Nucl Med. 1998 Jul;25(7):721-8 [9662594.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1875-80 [15536150.001]
  • [Cites] J Comput Assist Tomogr. 1992 Mar-Apr;16(2):248-53 [1545021.001]
  • [Cites] Eur J Nucl Med. 1998 Sep;25(9):1244-7 [9724372.001]
  • (PMID = 17021808.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Jarrett RF, Hjalgrim H, Hemminki K, van den Berg A, Olver B, Lloyd A, Dobbins SE, Lightfoot T, van Leeuwen FE, Försti A, Diepstra A, Broeks A, Vijayakrishnan J, Shield L, Lake A, Montgomery D, Roman E, Engert A, von Strandmann EP, Reiners KS, Nolte IM, Smedby KE, Adami HO, Russell NS, Glimelius B, Hamilton-Dutoit S, de Bruin M, Ryder LP, Molin D, Sorensen KM, Chang ET, Taylor M, Cooke R, Hofstra R, Westers H, van Wezel T, van Eijk R, Ashworth A, Rostgaard K, Melbye M, Swerdlow AJ, Houlston RS: A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet; 2010 Dec;42(12):1126-1130
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3).
  • To identify susceptibility loci for classical Hodgkin's lymphoma (cHL), we conducted a genome-wide association study of 589 individuals with cHL (cases) and 5,199 controls with validation in four independent samples totaling 2,057 cases and 3,416 controls.
  • [MeSH-major] Chromosomes, Human / genetics. GATA3 Transcription Factor / genetics. Genetic Loci / genetics. Genetic Predisposition to Disease. Genome-Wide Association Study. Hodgkin Disease / genetics. Proto-Oncogene Proteins c-rel / genetics
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 2 / genetics. Chromosomes, Human, Pair 8 / genetics. Female. Genome, Human / genetics. Humans. Male. Polymorphism, Single Nucleotide / genetics. Recombination, Genetic

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2008 Nov;40(11):1307-12 [18794855.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):537-48 [19017178.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Nat Rev Immunol. 2009 Feb;9(2):125-35 [19151747.001]
  • [Cites] J Virol. 2009 May;83(10):5014-27 [19264782.001]
  • [Cites] J Exp Med. 2009 May 11;206(5):981-9 [19380639.001]
  • [Cites] Int Immunopharmacol. 2009 May;9(5):590-2 [19539572.001]
  • [Cites] Int J Cancer. 2009 Sep 15;125(6):1334-42 [19507254.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):885-90 [19561604.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):882-4 [19561607.001]
  • [Cites] Nat Genet. 2009 Sep;41(9):1006-10 [19684604.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4239-46 [19667275.001]
  • [Cites] Nat Genet. 2010 Feb;42(2):132-6 [20062064.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6400-5 [20308568.001]
  • [Cites] Br J Haematol. 2010 Mar;148(5):739-53 [19958356.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] Int J Radiat Biol. 2000 May;76(5):693-8 [10866292.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1474-7 [11830502.001]
  • [Cites] Blood. 2002 Apr 15;99(8):3060-2 [11929801.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]
  • [Cites] Stat Med. 2002 Jun 15;21(11):1539-58 [12111919.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):489-95 [12478664.001]
  • [Cites] Blood. 2003 May 1;101(9):3681-6 [12511414.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S3-12 [12734687.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):971-80 [12837833.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):298-302 [12949811.001]
  • [Cites] J Clin Pathol. 2003 Nov;56(11):811-6 [14600123.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Hum Mol Genet. 2004 Jul 15;13(14):1479-85 [15163636.001]
  • [Cites] Stat Med. 1985 Jan-Mar;4(1):87-90 [3992076.001]
  • [Cites] Mol Cell Biol. 1986 May;6(5):1834-7 [3785181.001]
  • [Cites] Am J Hum Genet. 1987 Jan;40(1):1-14 [3468804.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):6964-8 [2402486.001]
  • [Cites] Oncogene. 1990 Sep;5(9):1359-64 [2216459.001]
  • [Cites] Mol Cell Biol. 1994 Feb;14(2):1039-44 [8289784.001]
  • [Cites] Am J Hum Genet. 1994 Mar;54(3):497-505 [8116619.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5101-5 [7923125.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3063-70 [10340377.001]
  • [Cites] Am J Pathol. 2005 Jan;166(1):127-34 [15632006.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] J Med Genet. 2005 Jul;42(7):595-601 [15994882.001]
  • [Cites] Science. 2005 Oct 14;310(5746):321-4 [16224025.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1243-6 [16228001.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D108-10 [16381825.001]
  • [Cites] Cell. 2006 Jan 13;124(1):47-59 [16413481.001]
  • [Cites] Int J Epidemiol. 2006 Feb;35(1):34-41 [16155052.001]
  • [Cites] Nat Genet. 2006 Jun;38(6):652-8 [16682969.001]
  • [Cites] PLoS Genet. 2005 Dec;1(6):e78 [16362079.001]
  • [Cites] Nat Genet. 2006 Aug;38(8):904-9 [16862161.001]
  • [Cites] Epidemiology. 2007 Jan;18(1):130-6 [17099321.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D122-6 [17148480.001]
  • [Cites] Science. 2007 Feb 9;315(5813):848-53 [17289997.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2382-8 [17332371.001]
  • [Cites] Genet Test. 2007 Spring;11(1):65-71 [17394394.001]
  • [Cites] Nat Genet. 2007 May;39(5):645-9 [17401363.001]
  • [Cites] Nat Genet. 2007 May;39(5):631-7 [17401366.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):661-78 [17554300.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):984-8 [17618284.001]
  • [Cites] EMBO J. 2007 Aug 8;26(15):3629-40 [17641686.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3310-5 [17630352.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1305-9 [17895893.001]
  • [Cites] Annu Rev Pathol. 2006;1:375-404 [18039120.001]
  • [Cites] Retrovirology. 2008;5:4 [18194563.001]
  • (PMID = 21037568.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C1298/A8362; United Kingdom / Wellcome Trust / / 076113; United Kingdom / Wellcome Trust / / 085475; United Kingdom / Wellcome Trust / / 068545/Z/02; United Kingdom / Cancer Research UK / / A3351; United Kingdom / Medical Research Council / / G0000934
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / Proto-Oncogene Proteins c-rel
  • [Other-IDs] NLM/ EMS32203; NLM/ PMC4268499
  •  go-up   go-down


24. Sadetzki S, Flint-Richter P: [Transgenerational effects of parental exposure to ionizing radiation]. Harefuah; 2006 Jul;145(7):516-21, 550, 549
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case-control study suggested an association between preconception irradiation and leukemia/non-Hodgkin's lymphoma in children of male workers at a nuclear plant in the UK (the Gardner hypothesis).
  • [MeSH-minor] Adult. Child. Female. Humans. Male. Pedigree. Pregnancy. Prenatal Exposure Delayed Effects

  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16900743.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Israel
  • [Number-of-references] 38
  •  go-up   go-down


25. Adelusola KA, Sabageh DO, Ukah CO: Lymphoreticular diseases in Nigerians. Afr Health Sci; 2008 Mar;8(1):20-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non Hodgkin's lymphoma (NHL) and tuberculosis were the most common lesions in lymph nodes and extranodal lymphoid tissues.
  • The most common pathological changes in bone marrow were NHL and reactive hyperplasia.
  • Patients with chronic lymphocytic leukaemia (CLL) had the highest mean age, which was significantly higher than in those with NHL (p=.001, 95% confidence interval -27.91 to -7.76).
  • CONCLUSION: NHL and tuberculosis should be high on the list of differential diagnosis of lymphadenopathy in Nigerians.
  • [MeSH-major] Burkitt Lymphoma. Lymphadenitis. Lymphoma, Non-Hodgkin. Tuberculosis, Lymph Node
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Bone Marrow / pathology. Child. Child, Preschool. Confidence Intervals. Data Interpretation, Statistical. Diagnosis, Differential. Female. Humans. Infant. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Lymphoid Tissue / pathology. Male. Middle Aged. Nigeria. Retrospective Studies. Spleen / pathology. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):327-30 [15101719.001]
  • [Cites] West Afr J Med. 2001 Apr-Jun;20(2):123-6 [11768010.001]
  • [Cites] Acta Trop. 1985 Mar;42(1):87-96 [2859755.001]
  • [Cites] J R Coll Surg Edinb. 1992 Feb;37(1):29-33 [1573603.001]
  • [Cites] Mod Pathol. 1993 May;6(3):378-91 [8346187.001]
  • [Cites] Q J Med. 1993 Dec;86(12):811-7 [8108537.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2459-64 [15621760.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):471-5 [15621842.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122 Suppl:S87-97 [15690645.001]
  • [Cites] Leuk Res. 2005 Dec;29(12):1371-80 [16183116.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] J Pathol. 1999 Dec;189(4):448-53 [10629542.001]
  • [Cites] Pediatr Surg Int. 2000;16(7):505-9 [11057553.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):76-80 [15185346.001]
  • (PMID = 19357728.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC2408537
  •  go-up   go-down


26. Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, Kuhlein E, Farcet JP, Emile JF, Gisselbrecht C, Delfau-Larue MH, Groupe d'étude des lymphomes de l'adulte: Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol; 2007 Jul;18(7):1209-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.
  • BACKGROUND: Lymphocytopenia is a prognostic factor in Hodgkin's disease.
  • In diffuse large B-cell lymphoma (DLBCL), data are much less established, in spite of numerous reports on immune system-lymphoma interactions.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496307.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


27. Wang XY, Wu N, Zhu Z, Zhao YF: Computed tomography features of enlarged tonsils as a first symptom of non-Hodgkin's lymphoma. Chin J Cancer; 2010 May;29(5):556-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computed tomography features of enlarged tonsils as a first symptom of non-Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVE: The tonsils are the most commonly involved primary part of non Hodgkin's lymphoma (NHL) of the head and neck, which usually happens in the Waldeyer's ring.
  • Our study describes the features of computed tomography on enlarged tonsils as a first symptom of NHL and the characteristics of the involved cervical lymph nodes.
  • CONCLUSIONS: Bilateral involvement, homogeneous density, and slight enhancement are characteristics of tonsil involvement of non Hodgkin's lymphoma.
  • [MeSH-major] Head and Neck Neoplasms / radiography. Lymph Nodes / pathology. Lymphoma, Non-Hodgkin / radiography. Palatine Tonsil / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Lymphatic Metastasis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiography. Male. Middle Aged. Neck. Neoplasm Invasiveness. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426908.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Fatnassi R, Bellara I: [Primary non-Hodgkin's lymphomas of the breast. Report of two cases]. J Gynecol Obstet Biol Reprod (Paris); 2005 Nov;34(7 Pt 1):721-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphomas of the breast. Report of two cases].
  • [Transliterated title] Les lymphomes malins non-hodgkiniens primitifs du sein: á propos de deux cas.
  • Non-hodgkin's lymphoma (NHL) represents 0.04 to 0.53% of all breast cancers.
  • We report two cases of primary non-hodgkin's lymphoma of the breast in two patients aged respectively 37 and 57 years.
  • The diagnosis of non-hodgkin's lymphoma was confirmed on histological examination of tumor biopsies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Biopsy. Female. Follow-Up Studies. Humans. Mammography. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270012.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


29. Aleman BM, Raemaekers JM, Tomiŝiĉ R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M, European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group: Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):19-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
  • PURPOSE: The use of radiotherapy in patients with advanced Hodgkin's lymphoma (HL) is controversial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Logistic Models. Male. Mechlorethamine / administration & dosage. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / mortality. Mediastinal Neoplasms / radiotherapy. Middle Aged. Neoplasms, Second Primary / etiology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Remission Induction. Survival Rate. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097834.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone
  •  go-up   go-down


30. Gergely L, Dankó A, Csípõ I, Váróczy L, Sipka S, Zeher M, Illés A: Antibodies against extractable nuclear antigen in non-Hodgkin lymphoma patients. Scand J Immunol; 2005 Apr;61(4):343-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibodies against extractable nuclear antigen in non-Hodgkin lymphoma patients.
  • We measured anti-extractable nuclear antigen (ENA) antibodies in non-Hodgkin's lymphoma patients before, during and after chemotherapy and compared these values to healthy controls.
  • Sixty six lymphoma patients' data were compared with 30 healthy patients' data.
  • ENA levels were significantly elevated in untreated lymphoma patients compared with healthy controls (1.85 U/l versus 0.68 U/l, P < 0.05).
  • [MeSH-major] Antigens, Nuclear / immunology. Antineoplastic Agents / therapeutic use. Autoantibodies / immunology. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853917.001).
  • [ISSN] 0300-9475
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Antineoplastic Agents; 0 / Autoantibodies
  •  go-up   go-down


31. Setty BA, Termuhlen AM: Rare pediatric non-hodgkin lymphoma. Curr Hematol Malig Rep; 2010 Jul;5(3):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare pediatric non-hodgkin lymphoma.
  • Of the cases of non-Hodgkin lymphoma (NHL) diagnosed in children and adolescents, 10% comprise a diverse mixture of unusual B-cell or T-cell disease, some types of which are more commonly seen in adults.
  • Understanding of these rare types of NHL comes from small pediatric case series or the adult literature.
  • Some rare pediatric NHL is similar to adult NHL, but other types have different molecular and cytogenetic characteristics.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Child. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):210-4 [16123999.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Br J Dermatol. 2006 Dec;155(6):1197-200 [17107389.001]
  • [Cites] J Dermatol. 2009 Jul;36(7):392-402 [19583687.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:349-58 [19074109.001]
  • [Cites] Leuk Lymphoma. 2006 May;47(5):865-9 [16753871.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Oct 15;170(2):158-62 [17011988.001]
  • [Cites] Pediatr Blood Cancer. 2009 May;52(5):566-70 [19058208.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Blood. 2005 Jan 1;105(1):74-6 [15353484.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1855-64 [11251018.001]
  • [Cites] Pediatr Blood Cancer. 2010 Feb;54(2):212-5 [19856396.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Mar;107(3):393-7 [19121958.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Pediatr Dev Pathol. 2004 Jul-Aug;7(4):407-13 [15455481.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3922-8 [10845929.001]
  • [Cites] Eur J Haematol. 2009 Sep;83(3):165-74 [19548917.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):123-30 [16236753.001]
  • [Cites] Semin Diagn Pathol. 1995 Nov;12(4):314-24 [8578026.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1782-9 [12721255.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):250-2 [15072617.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122 Suppl:S98-109 [15690646.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):29-33 [18300314.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33 Suppl 2:1-5 [16972944.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):229-34 [12067685.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):455-66 [1599024.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] Haematologica. 2000 Oct;85(10):1109-11 [11025614.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):220-3 [9792312.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):241-9 [12688340.001]
  • [Cites] Am J Hematol. 2004 Apr;75(4):195-9 [15054808.001]
  • [Cites] Blood. 2006 Jul 1;108(1):311-8 [16543468.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Haematologica. 2002 Dec;87(12):1258-64 [12495899.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1600-9 [18567836.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jan;133(1):142-6 [19123728.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Arch Dermatol. 2007 Dec;143(12):1520-6 [18087001.001]
  • [Cites] Blood. 1995 Jul 1;86(1):28-37 [7795234.001]
  • [Cites] Cancer. 1981 Nov 15;48(10):2223-35 [7028244.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Br J Haematol. 2008 Jul;142(3):329-47 [18537979.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):315-20 [15101717.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1959-64 [11877266.001]
  • (PMID = 20490722.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


32. Fajobi O, Jafri Z, Vadgama N, Cannon E, Myint F: Retroperitoneal non-Hodgkin's lymphoma presenting as periumbilical erythema. J Am Acad Dermatol; 2005 Sep;53(3):527-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal non-Hodgkin's lymphoma presenting as periumbilical erythema.
  • [MeSH-major] Erythema / etiology. Lymphoma, B-Cell / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Abdomen. Adult. Fatal Outcome. Female. Humans. Umbilicus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112369.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


33. Eilender D, LoRusso P, Thomas L, McCormick C, Rodgers AH, Hooper CL, Tornyos K, Krementz ET, Parker S, Morgan LR: 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers. Cancer Chemother Pharmacol; 2006 Jun;57(6):719-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: This is a multicenter study involving 27 patients with inoperable skin lesions from histologically confirmed cancers of the breast and oral cavity, non-Hodgkin's lymphoma, Kaposi's sarcoma, and angiosarcoma that had failed radiotherapy or systemic treatment.
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multicenter Studies as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184382.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 49310; United States / NCI NIH HHS / CA / CA 89772
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone; 0 / Antineoplastic Agents; 0 / Hydrazones; 0 / Phenols
  •  go-up   go-down


34. Xu YP, Guan M: [Non-Hodgkin's lymphoma in the subglottic region and the trachea]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Jan;42(1):68-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphoma in the subglottic region and the trachea].
  • [MeSH-major] Laryngeal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Tracheal Neoplasms / pathology
  • [MeSH-minor] Adult. Glottis / pathology. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17432363.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


35. Inokuchi M, Ito T, Uchikoshi M, Shimozuma Y, Morikawa K, Nozawa H, Shimazaki T, Hiroishi K, Miyakawa Y, Imawari M: Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. J Med Virol; 2009 Apr;81(4):619-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with hepatitis C virus (HCV) is associated with lymphoproliferative disorders, represented by essential mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma, but the pathogenic mechanism remains obscure.
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Female. Genes, Immunoglobulin Heavy Chain / genetics. Humans. Male. Middle Aged. Molecular Sequence Data. Prevalence. RNA, Viral / blood

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19235854.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


36. Decouvelaere AV, Morschhauser F, Buob D, Copin MC, Dumontet C: Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology; 2007 Apr;50(5):561-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Certain subtypes, such as mantle cell, lymphocytic or follicular lymphoma, were found to express PKC beta(2) in > 90% of the samples.
  • None of the cases of Hodgkin's disease and anaplastic large cell lymphoma expressed PKC beta(2).
  • In our series, the highest level of expression was found in mantle cell lymphomas and chronic lymphocytic lymphoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Female. Humans. Immunoenzyme Techniques. Isoenzymes / metabolism. Male. Middle Aged. Protein Kinase C beta

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394491.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
  •  go-up   go-down


37. Roh JL, Huh J, Suh C: Primary non-Hodgkin's lymphomas of the major salivary glands. J Surg Oncol; 2008 Jan 1;97(1):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphomas of the major salivary glands.
  • METHODS: We retrospectively assessed 20 patients with previously untreated non-Hodgkin's lymphomas (NHLs) and histologically confirmed as having parenchymal involvement of the salivary glands.
  • RESULTS: At diagnosis, the 12 patients with MALT lymphoma had a greater mean age and longer duration than did the 8 patients with other NHLs (P < 0.05).
  • Eight of the 12 MALT lymphoma patients had recurrent episodes of salivary gland swelling and 5 had myoepithelial sialadenitis, Sjögren syndrome, or gastric MALT lymphoma; these were not observed in the 8 other NHL patients.
  • Compared with the latter group, the MALT lymphoma group had significantly greater five-year relapse-free (37.5% vs. 91.7%, P < 0.05) and disease-free (35.0% vs. 90.9%, P < 0.05) survival rates.
  • However, two MALT lymphoma patients with high-grade transformation had recurrences beyond the head and neck region.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Lymphoma, B-Cell, Marginal Zone / mortality. Lymphoma, B-Cell, Marginal Zone / pathology. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17929252.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Franceschi S, Polesel J, Rickenbach M, Dal Maso L, Probst-Hensch NM, Fux C, Cavassini M, Hasse B, Kofler A, Ledergerber B, Erb P, Clifford GM: Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study. Br J Cancer; 2006 Dec 4;95(11):1598-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study.
  • Infections with hepatitis C virus (HCV) and, possibly, hepatitis B virus (HBV) are associated with an increased risk of non-Hodgkin's lymphoma (NHL) in the general population, but little information is available on the relationship between hepatitis viruses and NHL among people with HIV (PHIV).
  • Two hundred and ninety-eight NHL cases and 889 control subjects were matched by SHCS centre, gender, age group, CD4+ count at enrollment, and length of follow-up.
  • Odds ratios (OR) and corresponding 95% confidence intervals (CI) were computed using logistic regression to evaluate the association between NHL and seropositivity for antibodies against HCV (anti-HCV) and hepatitis B core antigen (anti-HBc), and for hepatitis B surface antigen (HBsAg).
  • Anti-HCV was not associated with increased NHL risk overall (OR = 1.05; 95% CI: 0.63-1.75), or in different strata of CD4+ count, age or gender.
  • No relationships between NHL risk and anti-HBc or HBsAg emerged.
  • Coinfection with HIV and HCV or HBV did not increase NHL risk compared to HIV alone in the SHCS.
  • [MeSH-major] HIV Infections / complications. Hepatitis C / complications. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Case-Control Studies. Cohort Studies. Female. Hepacivirus. Hepatitis B / complications. Hepatitis B virus. Homosexuality, Male. Humans. Male. Middle Aged. Risk Factors. Switzerland


39. Mwakigonja AR, Kaaya EE, Mgaya EM: Malignant lymphomas (ML) and HIV infection in Tanzania. J Exp Clin Cancer Res; 2008;27:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sections of 176 archival formalin-fixed paraffin-embedded biopsies of ML patients at Muhimbili National Hospital (MNH)/Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania from 1996-2001 were stained for hematoxylin and eosin and selected (70) cases for expression of pan-leucocytic (CD45), B-cell (CD20), T-cell (CD3), Hodgkin/RS cell (CD30), histiocyte (CD68) and proliferation (Ki-67) antigen markers.
  • RESULTS: The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was 4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and 22.16% Hodgkin's disease (HD).
  • Supra-diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-cell lymphomas however, no clear cases of primary effusion lymphoma (PEL) and primary central nervous system lymphoma (PCNSL) were diagnosed.
  • Therefore, routine HIV screening of all malignant lymphoma patients at MNH is necessary to enable comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / virology. Child. Child, Preschool. Female. HIV Seropositivity. Hodgkin Disease / epidemiology. Hodgkin Disease / etiology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Tanzania / epidemiology


40. Venizelos I, Tamiolakis D, Lambropoulou M, Nikolaidou S, Bolioti S, Papadopoulos H, Papadopoulos N: An unusual case of posttransplant peritoneal primary effusion lymphoma with T-cell phenotype in a HIV-negative female, not associated with HHV-8. Pathol Oncol Res; 2005;11(3):178-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of posttransplant peritoneal primary effusion lymphoma with T-cell phenotype in a HIV-negative female, not associated with HHV-8.
  • Primary effusion lymphoma (PEL) is a recently individualized form of non-Hodgkin's lymphoma (WHO classification) that mainly develops in HIV infected males, more frequently in homosexuals and advanced stages of the disease (total CD4+ lymphocyte count below 100-200/microL).
  • [MeSH-major] Herpesvirus 8, Human / isolation & purification. Kidney Transplantation / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, CD30 / analysis. Female. HIV Seronegativity. Homosexuality, Male. Humans. Immunophenotyping. Male. Postoperative Complications / pathology

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Respir J. 1999 Nov;14(5):1231-4 [10596717.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):595-601 [12002764.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5413-7 [2052620.001]
  • [Cites] Leukemia. 2000 Feb;14(2):271-7 [10673744.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1396-403 [7858270.001]
  • [Cites] Eur J Haematol. 2003 Jul;71(1):62-7 [12801300.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S56-67 [9894470.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):809-16 [14526684.001]
  • [Cites] Leuk Lymphoma. 2000 Feb;36(5-6):447-56 [10784388.001]
  • (PMID = 16195773.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30
  •  go-up   go-down


41. Pan SY, Mao Y, Ugnat AM, Canadian Cancer Registries Epidemiology Research Group: Physical activity, obesity, energy intake, and the risk of non-Hodgkin's lymphoma: a population-based case-control study. Am J Epidemiol; 2005 Dec 15;162(12):1162-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical activity, obesity, energy intake, and the risk of non-Hodgkin's lymphoma: a population-based case-control study.
  • The authors conducted a population-based case-control study of 1,030 cases with histologically confirmed, incident non-Hodgkin's lymphoma (NHL) and 3,106 controls to assess the impact of recreational physical activity, obesity, and energy intake on NHL risk in Canada from 1994 to 1997.
  • Some differences were found between histologic subtypes of NHL for these associations.
  • This study suggests that recreational physical activity decreases NHL risk, while obesity and excess calorie intake increase it.
  • [MeSH-major] Energy Intake. Lymphoma, Non-Hodgkin / epidemiology. Motor Activity. Obesity / complications
  • [MeSH-minor] Adult. Aged. Canada / epidemiology. Case-Control Studies. Female. Humans. Incidence. Logistic Models. Male. Middle Aged. Risk Factors. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269580.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kremer M, Ott G, Nathrath M, Specht K, Stecker K, Alexiou C, Quintanilla-Martinez L, Fend F: Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol; 2005 Jan;205(1):92-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine patients developed local relapse and one patient's tumour evolved into a B-cell non-Hodgkin's lymphoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD56 / metabolism. Cyclin D1 / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Retrospective Studies


43. Tzankov A, Zimpfer A, Went P, Maurer R, Pileri SA, Geley S, Dirnhofer S: Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. Mod Pathol; 2005 Jan;18(1):90-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma.
  • The characteristic Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma, although highly positive for proliferation markers, do not accumulate to excessive cell numbers.
  • We have previously described high expression of G1-phase cyclins in classical Hodgkin's lymphoma, which could explain the high percentage of cells staining for proliferation markers.
  • To further our understanding of proliferation control in classical Hodgkin's lymphoma, we extended our immunohistochemical analysis to the main S-phase cyclin, cyclin A, and its regulators p21CIP1 and p27KIP1.
  • In 47% (112/239) of classical Hodgkin's lymphoma cases p21CIP1 was detected within a mean frequency of 15% positive Hodgkin's and Reed-Sternberg cells per case.
  • Similarly, 47% (116/249) of the cases stained positively for p27KIP1 with a mean frequency of expression in Hodgkin's and Reed-Sternberg cells of 12%.
  • In contrast, 90% of the cells in all 246 evaluable classical Hodgkin's lymphoma cases were positive for PCNA.
  • In addition, 98% of Hodgkin's and Reed-Sternberg cells in 99% (250/253) of the cases stained strongly positive for cyclin A.
  • These findings further corroborate the hypothesis that Hodgkin and Reed-Sternberg cells exhibit a disturbed cell cycle with an abnormally short or even absent G1-phase.
  • [MeSH-major] Cell Cycle Proteins / analysis. Hodgkin Disease / pathology. Reed-Sternberg Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carrier Proteins / analysis. Child. Cyclin A / analysis. Cyclin D1 / analysis. Cyclin D3. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p21. Cyclin-Dependent Kinase Inhibitor p27. Cyclins / analysis. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / analysis. Male. Middle Aged. Proliferating Cell Nuclear Antigen / analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15389259.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND3 protein, human; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Carrier Proteins; 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Cyclin D3; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Proliferating Cell Nuclear Antigen; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


44. Fruehauf S, Veldwijk MR, Seeger T, Schubert M, Laufs S, Topaly J, Wuchter P, Dillmann F, Eckstein V, Wenz F, Goldschmidt H, Ho AD, Calandra G: A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy; 2009;11(8):992-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: PBPC obtained during G-CSF-supported mobilization before and after a supplementary administration of AMD3100 from patients with multiple myeloma and non-Hodgkin's lymphoma (n=15; phase II study) were investigated for co-expression of primitive and lineage-associated markers, their proliferative activity in vitro and repopulation potential after clinical transplantation.
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Antigens, CD38 / metabolism. Cell Culture Techniques. Drug Therapy, Combination. Europe. Female. Hematopoietic Stem Cell Transplantation. Humans. Leukocyte Count. Male. Middle Aged. Phenotype. Time Factors

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19929463.001).
  • [ISSN] 1477-2566
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Heterocyclic Compounds; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 155148-31-5 / JM 3100; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


45. Salehi M, Azimi Z, Fatemi F, Rajabi P, Kazemi M, Amini G: Incidence rate of mycosis fungoides in Isfahan (Iran). J Dermatol; 2010 Aug;37(8):703-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mycosis fungoides (MF) is an extranodal non-Hodgkin's lymphoma with primary involvement of the skin.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Iran / epidemiology. Male. Middle Aged

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20649711.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


46. Birgegård G, Gascón P, Ludwig H: Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol; 2006 Nov;77(5):378-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.
  • OBJECTIVES: Until recently, no prospective epidemiologic survey of lymphoma and multiple myeloma (L/MM) in European cancer patients had been conducted; furthermore, data on prevalence, incidence, and treatment patterns of L/MM were limited or unavailable.
  • Anemia prevalence during ECAS was 72.9% (MM, 85.3%; non-Hodgkin's lymphoma, 77.9%; Hodgkin's disease, 57.4%); incidence in chemotherapy patients was 55.4%.
  • [MeSH-major] Anemia / epidemiology. Lymphoma / epidemiology. Multiple Myeloma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Europe. Evaluation Studies as Topic. Female. Hemoglobins. Humans. Incidence. Male. Middle Aged. Neoplasm Staging / methods. Prevalence. Quality of Life. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1998 Aug;12(8):1281-7 [9697885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1047-56 [9719114.001]
  • [Cites] Med Oncol. 1998 Aug;15 Suppl 1:S29-34 [9785334.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1500-7 [10735898.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):172-9 [11328297.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2865-74 [11387359.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2875-82 [11387360.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 8):7-14 [11395846.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2214-21 [11413508.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1617-23 [11527686.001]
  • [Cites] Hematol J. 2002;3(3):121-30 [12111647.001]
  • [Cites] Wien Med Wochenschr. 2002;152(13-14):334-42 [12168517.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1109-15 [9834824.001]
  • [Cites] Haematologica. 1998 Nov;83(11):993-7 [9864919.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34 [10511589.001]
  • [Cites] Oncologist. 2004;9 Suppl 5:55-69 [15591423.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1797-802 [15479721.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2597-605 [15452188.001]
  • [Cites] Oncology. 2006;70(1):34-48 [16493206.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2303-20 [12239138.001]
  • [Cites] Mayo Clin Proc. 2003 Jan;78(1):21-33 [12528874.001]
  • [Cites] Oncologist. 2003;8 Suppl 1:27-30 [12626786.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):386-93 [12877665.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):394-403 [12877666.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1072-9 [12942577.001]
  • [Cites] Hematol Oncol. 2003 Dec;21(4):169-80 [14735555.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1301-7 [15051778.001]
  • [Cites] Eur J Cancer. 2004 Oct;40(15):2201-16 [15454245.001]
  • [Cites] Eur J Cancer. 2004 Oct;40(15):2293-306 [15454256.001]
  • [Cites] Mayo Clin Proc. 1975 Jan;50(1):29-40 [1110582.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1618-26 [1651993.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):88-91 [8538748.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):43-6 [9671330.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):54-7 [9671332.001]
  • (PMID = 17044835.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Hemoglobins
  • [Other-IDs] NLM/ PMC1618958
  •  go-up   go-down


47. Achemlal L, Mikdame M, Nouijai A, Bezza A, El Maghraoui A: Dramatical improvement of chemoresistant bone lymphoma with rituximab. Clin Rheumatol; 2006 May;25(3):394-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatical improvement of chemoresistant bone lymphoma with rituximab.
  • Non-Hodgkin's lymphoma of the bone is a very rare disease that accounts for approximately 5% of all extranodal non-Hodgkin's lymphomas and for 7-10% of primary bone tumours.
  • Biopsy revealed diffuse, large B-cell non-Hodgkin's lymphoma expressing CD20.
  • He had no evidence of recurrent lymphoma 24 months later.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Neoplasms / diagnosis. Drug Resistance, Neoplasm. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Humans. Humerus / diagnostic imaging. Humerus / pathology. Male. Radiography. Remission Induction. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Cancer. 1986 Dec 15;58(12):2646-55 [3779614.001]
  • [Cites] Ann Intern Med. 2001 Jun 19;134(12):1156-7 [11412072.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jan;184(1):185-92 [15615972.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1213-8 [10613315.001]
  • (PMID = 16247586.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


48. Cremonesi M, Ferrari M, Grana CM, Vanazzi A, Stabin M, Bartolomei M, Papi S, Prisco G, Ferrucci PF, Martinelli G, Paganelli G: High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. J Nucl Med; 2007 Nov;48(11):1871-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-two patients with refractory non-Hodgkin's lymphoma were enrolled into 3 activity groups escalating to 55.5 MBq/kg.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Tissue Distribution. Yttrium Radioisotopes

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Nucl Med. 2007 Dec;48(12):2027
  • (PMID = 17978355.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


49. Jin Y, Li YC, Su ZL, Tang LY, Feng ZY, Guo SZ: [Protein expressions of Fas and FasL in B-cell lymphoma and their significances]. Ai Zheng; 2005 Mar;24(3):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Protein expressions of Fas and FasL in B-cell lymphoma and their significances].
  • This study was designed to detect protein expressions of Fas and FasL in B-cell non-Hodgkin's lymphoma (B-NHL) and benign lymphoid tissue, and to provide new markers for diagnosis of lymphoma.
  • METHODS: Immunohistochemistry was used to detect protein expressions of Fas and FasL in 92 specimens of B-NHL, and 20 specimens of benign lymphoid tissue.
  • Positive rate of Fas in B-NHL was 66.3% (61/92), and that of FasL in B-NHL was 67.4% (62/92).
  • There was no significant difference in expressions of Fas and FasL between B-NHL group and benign group (P>0.05), but positive locations of Fas and FasL in these 2 groups are different.
  • Positive rates of Fas and FasL were higher in diffuse large B-cell lymphoma (DLBL) than in follicular lymphoma (FL), and small cell lymphoma (SLL) (87.2% vs. 64.5%, and 31.8%, P<0.05u 89.7% vs. 67.7%, and 27.3%, P<0.05).
  • CONCLUSIONS: The expressions of Fas and FasL are not useful for distinguishing benign lymphoid tissue from lymphoma tissue, while their locational characteristics are valuable for differential diagnosis.
  • The expressions of Fas and FasL are considered valuable in evaluating the malignant grade of B-NHL.
  • [MeSH-major] Antigens, CD95 / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Follicular / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Membrane Glycoproteins / metabolism. Tumor Necrosis Factors / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Membrane / metabolism. Child. Child, Preschool. Cytoplasm / metabolism. Diagnosis, Differential. Fas Ligand Protein. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell. Lymphadenitis / metabolism. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757536.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Tumor Necrosis Factors
  •  go-up   go-down


50. Guven S, Ozcebe OI, Tuncer ZS: Non-Hodgkin's lymphoma complicating pregnancy: a case report. Eur J Gynaecol Oncol; 2005;26(4):457-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma complicating pregnancy: a case report.
  • Histologic examination of the excised lymph node revealed non-Hodgkin's lymphoma (Histiocyte and T cell predominant B cell lymphoma).
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cesarean Section. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122204.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


51. Ozer N, Deveci OS, Kaya EB, Demircin M: Mediastinal lymphoma causing extrinsic pulmonary stenosis. Turk Kardiyol Dern Ars; 2009 Sep;37(6):421-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal lymphoma causing extrinsic pulmonary stenosis.
  • Extrinsic pulmonic stenosis is even rarer and predominantly caused by external thoracic masses creating non-dynamic obstruction of the right ventricular outflow tract.
  • The pathological diagnosis of the mass was stage IIa nodular sclerosing Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / complications. Mediastinal Neoplasms / complications. Pulmonary Valve Stenosis / etiology
  • [MeSH-minor] Echocardiography, Transesophageal. Female. Humans. Pulmonary Artery / surgery. Pulmonary Artery / ultrasonography. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20019459.001).
  • [ISSN] 1016-5169
  • [Journal-full-title] Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
  • [ISO-abbreviation] Turk Kardiyol Dern Ars
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


52. Sajid T, Intisar-ul-Haq, Haq I, Chaudhary AK: An obscure cause of leg edema, non-Hodgkin's lymphoma. J Coll Physicians Surg Pak; 2009 Apr;19(4):254-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An obscure cause of leg edema, non-Hodgkin's lymphoma.
  • Later, she turned out to be a case of non-Hodgkin's lymphoma.
  • This presentation is contrary to usual age and mode of presentation of non-Hodgkin's lymphoma.
  • [MeSH-major] Edema / etiology. Leg / pathology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Female. Humans. Risk Factors

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356344.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


53. Yu GP, Schantz SP, Neugut AI, Zhang ZF: Incidences and trends of second cancers in female breast cancer patients: a fixed inception cohort-based analysis (United States). Cancer Causes Control; 2006 May;17(4):411-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Between the 1970s and the 1990s, the incidence rate of malignant second cancer significantly increased among female breast cancer patients, of which second non-Hodgkin's lymphoma and kidney cancer increased by about 150%, while second cancers of the thyroid, uterine corpus and skin melanoma increased 80%, and cancer of the lung increased 50%.
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Incidence. Middle Aged. Odds Ratio. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596293.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


54. Hirose A, Yamane T, Nakajima Y, Manabe M, Kanashima H, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Kosaka S, Aoyama Y, Sakamoto C, Kumura T, Koh KR, Hirai M, Ohta K, Nakao Y, Mugitani A, Teshima H, Hino M: [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2059-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
  • To evaluate the results of high-dose chemotherapy (HDT) and autologous hematopoietic stem cell transplantation (ASCT) in patients with diffuse B-cell aggressive non-Hodgkin's lymphoma(NHL).
  • Of 25 patients with refractory NHL,14 were chemotherapy-sensitive before HDT-ASCT and 11 were chemotherapy-resistant.
  • HDT-ASCT should be considered for patients with refractory aggressive NHL who are chemotherapy-sensitive rather than chemotherapy-resistant.
  • In future, HDT-ASCT combined with rituximab as induction therapy or as consolidation therapy is needed for patients with aggressive NHL in the high-risk group.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Transplantation, Autologous
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352929.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RYH2T97J77 / ranimustine
  •  go-up   go-down


55. Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, Pruneri G, Radice D, Pinto A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G: Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol; 2010 May 1;28(13):2233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No patients developed transformation to high-grade non-Hodgkin's lymphoma nor myelodysplasia.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cladribine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Genotype. Humans. Immunophenotyping. Injections, Subcutaneous. Italy. Kaplan-Meier Estimate. Male. Membrane Transport Proteins / genetics. Membrane Transport Proteins / metabolism. Middle Aged. Patient Selection. Phenotype. Prospective Studies. Rituximab. Time Factors. Treatment Outcome. ZAP-70 Protein-Tyrosine Kinase / genetics. ZAP-70 Protein-Tyrosine Kinase / metabolism


56. Kiserud CE, Loge JH, Fosså A, Holte H, Cvancarova M, Fosså SD: Mortality is persistently increased in Hodgkin's lymphoma survivors. Eur J Cancer; 2010 Jun;46(9):1632-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality is persistently increased in Hodgkin's lymphoma survivors.
  • Aims of this study were to examine mortality and causes of death in Hodgkin's lymphoma survivors (HLSs) compared to controls from the general population, and to explore if CF was associated with increased mortality.
  • METHODS: HLSs (n=557) invited to participate in a survey on late effects in 1994 were divided into three groups: participants without CF (n=329), participants with CF (n=113), non-participants (n=98).
  • Mortality was increased in all groups: participants with CF: HR=4.85 (95% CI: 3.02-7.77), participants without CF: HR=4.35 (95% CI: 3.16-6.00), non-participants: HR=9.45 (95% CI: 5.44-16.41).
  • The high mortality among the non-participating HLSs indicates that serious health problems are underestimated in this group.
  • [MeSH-major] Fatigue / mortality. Hodgkin Disease / mortality. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Cause of Death. Chronic Disease. Disease-Free Survival. Female. Humans. Male. Middle Aged. Norway / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20219350.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Stanojević GZ, Stojanović MP, Stojanović MM, Krivokapić Z, Jovanović MM, Katić VV, Jeremić MM, Branković BR: Non-Hodgkin's lymphomas of the large bowel-clinical characteristics, prognostic factors and survival. Acta Chir Iugosl; 2008;55(3):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the large bowel-clinical characteristics, prognostic factors and survival.
  • The aims of this study were to review the clinical presentation of non-Hodgkin's lymphomas of the large bowel, to analyze the prognostic factors using univariate and multivariate methods, as well as the overall survival.
  • Our results showed that tumor stage and operation type should be considered as the most important prognostic factors in patients with primary non-Hodgkin's lymphomas of the large bowel.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069702.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


58. El Cheikh J, de Colella JM, Vacher-Copponat H, Moal V, Costello RT: Non-Hodgkin's lymphoma after kidney transplantation: a single institution study. Leuk Res; 2006 Jan;30(1):118-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma after kidney transplantation: a single institution study.
  • We treated at our institution six patients with kidney transplantation and lymphoma.
  • These preliminary data suggest that, after lymphoma treatment, immune suppression can be withhold at least for 2 years.
  • Restoration of a functional immune system may contribute to decrease the rate of lymphoma recurrence, in line with the absence of lymphoma relapse in our six patients, who are all still alive and in complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Kidney Transplantation. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Immunosuppression. Male. Middle Aged. Prednisone / administration & dosage. Recurrence. Remission Induction. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982732.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


59. Willenbrock K, Kriener S, Oeschger S, Hansmann ML: Nodular lymphoid lesion of the liver with simultaneous focal nodular hyperplasia and hemangioma: discrimination from primary hepatic MALT-type non-Hodgkin's lymphoma. Virchows Arch; 2006 Feb;448(2):223-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lymphoid lesion of the liver with simultaneous focal nodular hyperplasia and hemangioma: discrimination from primary hepatic MALT-type non-Hodgkin's lymphoma.
  • The discrimination of NLL from primary hepatic malignant non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue-type may pose diagnostic difficulties and may require the use of immunohistochemical and molecular techniques.
  • [MeSH-minor] Adult. Antigens, CD20 / analysis. Antigens, CD3 / analysis. B-Lymphocytes / chemistry. B-Lymphocytes / pathology. Clone Cells / chemistry. Clone Cells / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymphocytes / chemistry. Lymphocytes / pathology. Lymphoma, B-Cell, Marginal Zone / metabolism. Lymphoma, B-Cell, Marginal Zone / pathology. T-Lymphocytes / chemistry. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1997 Jan;26(1):209-14 [9148014.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):716-9 [10420230.001]
  • [Cites] J Clin Gastroenterol. 1993 Apr;16(3):240-4 [8505499.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2489-95 [12456507.001]
  • [Cites] Hepatology. 2003 Apr;37(4):781-7 [12668970.001]
  • [Cites] Pathol Int. 1994 Sep;44(9):704-11 [7804433.001]
  • [Cites] Intern Med. 1994 Jan;33(1):18-22 [7514058.001]
  • [Cites] J Hepatol. 1997 Nov;27(5):922-7 [9382982.001]
  • [Cites] Z Gastroenterol. 2001 Mar;39(3):219-24 [11324139.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Pathol Int. 1996 Oct;46(10):782-6 [8916149.001]
  • [Cites] Am J Surg Pathol. 1995 May;19(5):571-5 [7726367.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Feb;14 (2):163-7 [10029298.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):604-8 [10747320.001]
  • [Cites] Am J Surg Pathol. 1999 Mar;23(3):302-8 [10078921.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):404-10 [9578094.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Scand J Rheumatol. 2001;30(2):117-9 [11324789.001]
  • (PMID = 16331470.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


60. Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL, Cancer and Leukemia Group B: Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma; 2006 Aug;47(8):1511-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.
  • Patients with relapsed or refractory aggressive non-Hodgkin's lymphomas (NHL) were eligible for this phase II study of doxorubicin 25 mg/m2 intravenous (IV) on day 1 and topotecan 1.75 mg/m2/day IV on days 3 - 5, every 21 days.
  • Both patients achieving a complete remission had Burkitt's lymphoma.
  • In conclusion, the combination of doxorubicin and topotecan is well tolerated and has modest activity in relapsed/refractory NHL, with occasional patients having a prolonged remission.
  • The activity in Burkitt's lymphoma should be investigated further.
  • [MeSH-major] Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Salvage Therapy / methods. Topotecan / administration & dosage
  • [MeSH-minor] Adult. Aged. Burkitt Lymphoma / drug therapy. Disease-Free Survival. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Topoisomerase I Inhibitors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966261.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA86726
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin
  •  go-up   go-down


61. Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C: BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol; 2008 Jan;87(1):43-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
  • The treatment of choice for relapsed/refractory non-Hodgkin's lymphoma (NHL) consists of high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT).
  • Little is known, however, regarding the comparative toxicity and efficacy of various HDC regimens applied in NHL.
  • Between April 1994 and February 2005, 97 NHL patients underwent HDC with BEAC (N = 69) or BEAM (N = 28), followed by ASCT, at the Asan Medical Center.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / surgery
  • [MeSH-minor] Adolescent. Adult. Carmustine / adverse effects. Carmustine / therapeutic use. Cytarabine / adverse effects. Cytarabine / therapeutic use. Female. Humans. Male. Melphalan / adverse effects. Melphalan / therapeutic use. Middle Aged. Podophyllotoxin / adverse effects. Podophyllotoxin / therapeutic use. Retrospective Studies. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710401.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM protocol
  •  go-up   go-down


62. Visser O, van Leeuwen FE: Cancer risk in first generation migrants in North-Holland/Flevoland, The Netherlands, 1995-2004. Eur J Cancer; 2007 Mar;43(5):901-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High risks in migrants from non-western countries were observed for cancer of the nasopharynx (China 51, Morocco 22), liver (China 13), gallbladder, cervix and thyroid, as well as for Kaposi's sarcoma, Hodgkin's lymphoma and mature T/NK-cell lymphoma.
  • Although cancers related to infectious disease were relatively common among migrants from non-western countries, the low risks for mainly lifestyle related cancers resulted in a low overall risk.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Netherlands / epidemiology. Poisson Distribution. Risk Factors. Sex Distribution

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258450.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Wright J, Johnson P, Smith P, Horsman JM, Hancock BW: T-cell non-Hodgkin's lymphoma: treatment outcomes and survival in 3 large UK centres. Acta Haematol; 2007;118(2):123-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell non-Hodgkin's lymphoma: treatment outcomes and survival in 3 large UK centres.
  • [MeSH-major] Lymphoma, T-Cell / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Great Britain / epidemiology. Hematopoietic Stem Cell Transplantation. Humans. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785961.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  •  go-up   go-down


64. Nistala SS, Sawalakhe NR, Thiruvengadam NR, Rathi PM: A rare case of primary pancreatic Burkitt lymphoma in a young Indian male. Case report and review of the literature. JOP; 2009;10(6):686-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of primary pancreatic Burkitt lymphoma in a young Indian male. Case report and review of the literature.
  • CONTEXT: Lymphomas of the gastrointestinal system are usually of a non-Hodgkin's type.
  • Primary lymphomas of the pancreas are uncommon and Burkitt lymphoma involving the pancreas is very rare.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Humans. India. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890195.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 13
  •  go-up   go-down


65. Penel N, Vansteene D: [Cancers and pesticides: current data]. Bull Cancer; 2007 Jan;94(1):15-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occupational exposure to pesticide increases the risk of non-Hodgkin's lymphoma and hairy cells leukaemia.
  • [MeSH-minor] Adult. Child. Female. Humans. Leukemia, Hairy Cell / chemically induced. Liver Neoplasms / chemically induced. Lung Neoplasms / chemically induced. Lymphoma, Non-Hodgkin / chemically induced. Male. Paternal Exposure / adverse effects. Sarcoma / chemically induced

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237001.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Pesticides
  • [Number-of-references] 63
  •  go-up   go-down


66. Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N: Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis; 2006 Sep;65(9):1184-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study.
  • BACKGROUND: Several inflammatory conditions are associated with an increased risk of lymphoma.
  • There are few studies on whether ankylosing spondylitis increases the risk of lymphoma.
  • Besides inflammation-lymphoma aetiology, information on risk of lymphoma in ankylosing spondylitis is particularly important as a benchmark in the evaluation of, for example, tumour necrosis factor inhibitors.
  • METHODS: The association between ankylosing spondylitis and malignant lymphomas overall, and separately for non-Hodgkin's lymphoma, Hodgkin's lymphoma and chronic lymphocytic leukaemia, was assessed in a nationwide, population-based case-control study of 50 615 cases of lymphoma and 92 928 matched controls by using prospectively recorded data on lymphomas from the Swedish Cancer Register (1964-2000) and data on pre-lymphoma hospitalisations for ankylosing spondylitis from the Swedish Inpatient Register (1964-2000).
  • The odds ratios (ORs) associated with pre-lymphoma hospitalisation for ankylosing spondylitis were calculated using conditional logistic regression.
  • RESULTS: 23 (0.05%) patients with lymphoma and 41 (0.05%) controls had a pre-lymphoma hospitalisation listing ankylosing spondylitis, relative risk = 1.0 (95% confidence interval (CI) 0.6 to 1.7).
  • The number of discharges and the mean latency between ankylosing spondylitis and lymphoma were similar in patients and controls.
  • CONCLUSIONS: On average and in the absence of tumour necrosis factor inhibitors, patients hospitalised with ankylosing spondylitis do not appreciably show an increased risk of lymphoma.
  • [MeSH-major] Lymphoma / etiology. Spondylitis, Ankylosing / complications
  • [MeSH-minor] Adult. Aged. Epidemiologic Methods. Female. Hospitalization / statistics & numerical data. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Male. Middle Aged. Sweden / epidemiology


67. Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ: Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant; 2006 Dec;12(12):1326-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
  • Reduced-intensity regimens (RIRs) are being used with increasing frequency in patients with non-Hodgkin's lymphoma (NHL) undergoing allogeneic transplantation.
  • Our observation of similar survival in the patients receiving CMR and those receiving RIR confirms that RIRs are feasible alternatives for high-risk patients with NHL; however, the data suggest that reduced treatment intensity and previous autologous transplantation are associated with increased relapse.
  • [MeSH-major] Lymphoma, Non-Hodgkin / surgery. Peripheral Blood Stem Cell Transplantation / statistics & numerical data. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Busulfan / administration & dosage. Busulfan / adverse effects. Cause of Death. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Hepatic Veno-Occlusive Disease / etiology. Hepatic Veno-Occlusive Disease / mortality. Humans. Infection / etiology. Infection / mortality. Kaplan-Meier Estimate. Lung Diseases, Interstitial / etiology. Lung Diseases, Interstitial / mortality. Lymphoma, Follicular / mortality. Lymphoma, Follicular / surgery. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / surgery. Lymphoma, Mantle-Cell / mortality. Lymphoma, Mantle-Cell / surgery. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / surgery. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Postoperative Complications / etiology. Postoperative Complications / mortality. Proportional Hazards Models. Reoperation / statistics & numerical data. Retrospective Studies. Risk Factors. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives. Whole-Body Irradiation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162215.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


68. Matalliotakis I, Cakmak H, Fragouli Y, Zervoudis S, Neonaki M, Arici A: Association of endometriosis with family history of non-Hodgkin's lymphoma: presentation of 10 cases. J BUON; 2009 Oct-Dec;14(4):699-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of endometriosis with family history of non-Hodgkin's lymphoma: presentation of 10 cases.
  • PURPOSE: Women with endometriosis have been reported to be at increased risk of developing non-Hodgkin's lymphoma (NHL).
  • The purpose of this article was to investigate the familial risk of NHL in women with endometriosis.
  • We report on 10 cases with endometriosis and positive family history of NHL.
  • Ten cases of endometriosis having first-degree relatives with NHL are reported.
  • RESULTS: We found no case with endometriosis and NHL.
  • In contrast, we found 10/405 (2.5%) women with endometriosis and first-degree relatives with NHL.
  • All of these patients had first-degree relatives with a history of NHL.
  • Five had mothers with NHL, 5 had fathers and one had a sister.
  • CONCLUSION: These cases could suggest a link between a family history of NHL and subsequent development of endometriosis in the first-generation women.
  • Moreover, there was no evidence of association between endometriosis and NHL.
  • [MeSH-major] Endometriosis / etiology. Genetic Predisposition to Disease. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148465.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


69. Bociek RG: Adult Burkitt's lymphoma. Clin Lymphoma; 2005 Jun;6(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt's lymphoma.
  • Burkitt's lymphoma is a mature B-cell lymphoma that is characterized by a rapid proliferative rate and propensity for extranodal sites of involvement such as the gastrointestinal tract and central nervous system.
  • This subtype of non-Hodgkin's lymphoma is associated with unique cytogenetic translocations involving the c-MYC oncogene on chromosome 8, which appears to be involved in the pathogenesis of this disease.
  • Although current literature is limited by a lack of randomized trials, Burkitt's lymphoma appears to be curable in a high proportion of cases if treated with aggressive multiagent chemotherapy regimens.
  • Patients with HIV-associated Burkitt's lymphoma appear to have a better prognosis today, which is likely a result of more effective antiretroviral therapy and the ability to treat selected patients with more aggressive chemotherapeutic regimens than before.
  • This article will review the epidemiologic, biologic, diagnostic, and therapeutic aspects of Burkitt's lymphoma in adults.
  • [MeSH-major] Burkitt Lymphoma
  • [MeSH-minor] Adult. Humans

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989701.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


70. Park SK, Kang D, Beane-Freeman L, Blair A, Hoppin JA, Sandler DP, Lynch CF, Knott C, Gwak J, Alavanja M: Cancer incidence among paraquat exposed applicators in the agricultural health study: prospective cohort study. Int J Occup Environ Health; 2009 Jul-Sep;15(3):274-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the total subjects, the risk for non-Hodgkin's lymphoma (NHL) in the exposed group was marginally elevated (Relative risk [RR], 1.47; 95% confidence interval [CI], 0.97-2.23) compared to the non-exposed group.
  • However, among the 24,667 applicators who supplied total life-time exposure days, the highest tertile of lifetime exposure-days (LE) and intensity-weighted lifetime exposure-days (IWLE) was not significantly associated with NHL risk (RR, 1.57; 95%CI, 0.57-4.23 for LE; RR, 1.42; 95%CI, 0.40-4.71 for IWLE, respectively) and there was no significant exposure-response trend (p-trend > 0.1).
  • There was some suggestion of a possible link between paraquat exposure and NHL risk in humans, but the inconsistency in exposure level trend suggests that this could be a chance finding.
  • [MeSH-major] Agricultural Workers' Diseases / epidemiology. Herbicides / toxicity. Lymphoma, Non-Hodgkin / epidemiology. Paraquat / toxicity
  • [MeSH-minor] Adult. Female. Humans. Incidence. Iowa / epidemiology. Male. Middle Aged. North Carolina / epidemiology. Prospective Studies. Risk

  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Paraquat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Dermatol. 1995 Jul;34(7):466-9 [7591408.001]
  • [Cites] Int J Radiat Biol. 1991 Dec;60(6):899-906 [1682402.001]
  • [Cites] Br J Ind Med. 1987 Mar;44(3):196-200 [3493801.001]
  • [Cites] Hum Toxicol. 1987 Jan;6(1):41-7 [3546085.001]
  • [Cites] Biochem Biophys Res Commun. 1979 Dec 28;91(4):1302-8 [526305.001]
  • [Cites] Cell Tissue Res. 2004 Oct;318(1):225-41 [15258850.001]
  • [Cites] Toxicol Lett. 2004 Jun 15;151(1):69-78 [15177642.001]
  • [Cites] Pest Manag Sci. 2004 Apr;60(4):340-9 [15119596.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):313-8 [12198579.001]
  • [Cites] Ann Occup Hyg. 2002 Mar;46(2):245-60 [12074034.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Mar 1;165(5):683-9 [11874814.001]
  • [Cites] Epidemiology. 2002 Jan;13(1):94-9 [11805592.001]
  • [Cites] Mutat Res. 1993 Oct;319(2):89-101 [7692291.001]
  • [Cites] Int J Occup Environ Health. 2001 Oct-Dec;7(4):275-86 [11783857.001]
  • [Cites] Mutat Res. 1995 Apr;328(1):113-8 [7898500.001]
  • [Cites] Int J Epidemiol. 1999 Jun;28(3):365-74 [10405835.001]
  • [Cites] Environ Health Perspect. 1996 Apr;104(4):362-9 [8732939.001]
  • [Cites] Mutat Res. 1993 Aug;300(3-4):223-9 [7687022.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):809-12 [9635867.001]
  • [Cites] Teratog Carcinog Mutagen. 1997-1998;17(6):339-47 [9485542.001]
  • [Cites] Int J Epidemiol. 1996 Dec;25(6):1125-31 [9027515.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103 Suppl 8:205-8 [8741784.001]
  • (PMID = 19650582.001).
  • [ISSN] 1077-3525
  • [Journal-full-title] International journal of occupational and environmental health
  • [ISO-abbreviation] Int J Occup Environ Health
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010119-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Herbicides; PLG39H7695 / Paraquat
  • [Other-IDs] NLM/ NIHMS232258; NLM/ PMC3058830
  •  go-up   go-down


71. Maldonado F, Pittelkow MR, Ryu JH: Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology; 2009 Jan;14(1):129-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-Hodgkin's lymphoma and chronic lymphocytic leukaemia were the underlying neoplasms in over two-thirds of these patients.
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Treatment Failure

  • Genetic Alliance. consumer health - Constrictive Bronchiolitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144057.001).
  • [ISSN] 1440-1843
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 13
  •  go-up   go-down


72. Neal RD, Allgar VL: Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the "National Survey of NHS Patients: Cancer". Br J Cancer; 2005 Jun 6;92(11):1971-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper aims to explore the relationship between sociodemographic factors and the components of diagnostic delay (total, patient and primary care, referral, secondary care) for these six cancers (breast, colorectal, lung, ovarian, prostate, or non-Hodgkin's lymphoma).
  • With regard to total delay, the findings from the GLM showed that for colorectal cancer, the significant factors were marital status and age, for lung and ovarian cancer none of the factors were significant, for prostate cancer the only significant factor was social class, for non-Hodgkin's lymphoma the only significant factor was age, and for breast cancer the significant factors were marital status and ethnic group.
  • [MeSH-minor] Adult. Aged. Continental Population Groups. Demography. Ethnic Groups. Female. Great Britain. Health Care Surveys. Humans. Male. Middle Aged. Primary Health Care / standards. Primary Health Care / statistics & numerical data. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Care. 2000 Jan;38(1):108-14 [10630725.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):742-8 [10682692.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1034-40 [11953844.001]
  • [Cites] N Z Med J. 2002 Nov 22;115(1166):U257 [12552275.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1959-70 [15870714.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1595-604 [15073845.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1479-85 [15083172.001]
  • [Cites] World J Surg. 2004 Jul;28(7):716-20 [15383871.001]
  • [Cites] Ann Surg. 1999 Jan;229(1):91-6 [9923805.001]
  • [Cites] World J Surg. 2003 Mar;27(3):304-8 [12607056.001]
  • (PMID = 15900296.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361785
  •  go-up   go-down


73. Laszlo D, Rabascio C, Andreola G, Pruneri G, Raia V, Calabrese L, Radice D, Saronni L, Martinelli G: Chlorambucil - rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: a clinical and biological analysis. Leuk Lymphoma; 2007 Feb;48(2):437-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlorambucil - rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: a clinical and biological analysis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Chlorambucil / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Rituximab

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325914.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 18D0SL7309 / Chlorambucil; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


74. Kanbay M, Altundag K, Gur G, Boyacioglu S: Non-Hodgkin's lymphoma presenting with granulomatous hepatitis and hemophagocytosis. Leuk Lymphoma; 2006 Apr;47(4):767-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting with granulomatous hepatitis and hemophagocytosis.
  • [MeSH-major] Granuloma / diagnosis. Hepatitis / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Phagocytosis
  • [MeSH-minor] Adult. Bone Marrow Cells / metabolism. Diagnosis, Differential. Hematologic Diseases / diagnosis. Humans. Lymphoma / metabolism. Male


75. Anunobi CC, Banjo AA, Abdulkareem FB, Daramola AO, Akinde RO, Abudu EK: Adult lymphomas in Lagos Nigeria: a fourteen year study. Nig Q J Hosp Med; 2007 Apr-Jun;17(2):63-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult lymphomas in Lagos Nigeria: a fourteen year study.
  • OBJECTIVE: we present a 14 year retrospective histopathological study of 92 cases of adult lymphomas in Lagos.
  • MATERIALS AND METHOD: The materials consisted of slides and paraffin embedded blocks of all cases of lymphoma in adults above the age of 16 years seen between 1991 and 2004 at the Morbid Anatomy Department of Lagos University Teaching Hospital Idi-Araba Lagos.
  • RESULTS: Of ninety two cases of lymphoma studied, male and female patients accounted for 59(64%) and 33(36%) cases respectively, giving a M: F ratio of 1.8:1.
  • Non-Hodgkin's lymphoma (NHL) which accounted for 60 cases occurred most frequently in the 46-55 years age group and gives a male: female ratio of 2:1.
  • Hodgkin's lymphoma mostly affected patients of younger age group, 25-35 years with a M:F ratio of 1.7:1.
  • Mixed cellularity 17 (55%) was the commonest subtype of Hodgkin's lymphoma.
  • CONCLUSION: Non-Hodgkin's lymphoma is commoner than Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Female. Humans. Male. Middle Aged. Nigeria / epidemiology. Retrospective Studies. Sex Distribution

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318094.001).
  • [ISSN] 0189-2657
  • [Journal-full-title] Nigerian quarterly journal of hospital medicine
  • [ISO-abbreviation] Nig Q J Hosp Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


76. Wang SL, Liao ZX, Liu XF, Yu ZH, Gu DZ, Qian TN, Song YW, Jin J, Wang WH, Li YX: Primary early-stage intestinal and colonic non-Hodgkin's lymphoma: clinical features, management, and outcome of 37 patients. World J Gastroenterol; 2005 Oct 7;11(37):5905-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary early-stage intestinal and colonic non-Hodgkin's lymphoma: clinical features, management, and outcome of 37 patients.
  • AIM: To analyze the clinical features, management, and outcome of treatment of patients with primary intestinal and colonic non-Hodgkin's lymphoma (PICL).
  • [MeSH-major] Colonic Neoplasms / pathology. Intestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270408.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4479699
  •  go-up   go-down


77. Abid MB, Nasim F, Anwar K, Pervez S: Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic? Asian Pac J Cancer Prev; 2005 Oct-Dec;6(4):531-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic?
  • There has been a recent concern among oncological clinicians and pathologists of our region regarding the disproportionate increase in the number of patients presenting with diffuse large B cell lymphoma (DLBCL).
  • A total of 780 specimens were collected over last half decade from cases classified as adult Non Hodgkin's lymphoma (NHL).
  • Nodal-NHLs constituted 42.2 % of all adult NHLs, with the cervical lymph nodes as the most frequent nodal site of presentation.
  • [MeSH-major] Disease Outbreaks. Lymphoma, B-Cell / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Prevalence. Sex Distribution

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16436006.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


78. Cohn DE, Resnick KE, Eaton LA, deHart J, Zanagnolo V: Non-Hodgkin's lymphoma mimicking gynecological malignancies of the vagina and cervix: a report of four cases. Int J Gynecol Cancer; 2007 Jan-Feb;17(1):274-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma mimicking gynecological malignancies of the vagina and cervix: a report of four cases.
  • Although in the past two decades there has been a sharp rise in the incidence of extranodal primary lymphomas in the United States, non-Hodgkin's lymphoma (NHL) of the female genital tract is still rare.
  • We present four cases of extranodal NHL presenting with signs and symptoms consistent with cancer of the vagina or cervix and lacking the "B" symptoms often associated with systemic lymphoma such as fever, weight loss, night sweat, and fatigue.
  • It is important for gynecologists to be aware of this neoplastic disease and to include cervical or vaginal lymphoma in the differential diagnosis of patients presenting with examinations suggestive of cervical or vaginal cancer.
  • A correct diagnosis leads to the appropriate therapy, and radical gynecological surgery can be avoided for primary cervical and vaginal lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Middle Aged


79. Güler N, Yilmaz S, Ayaz S, Yilmaz M, Aki Z, Dağdaş S, Gökmen A, Ozet G: The plateled-derived growth factor level (PDGF) in Hodgkin's disease and non-Hodgkin's lymphoma and its relationship disease activation. Hematology; 2005 Feb;10(1):53-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The plateled-derived growth factor level (PDGF) in Hodgkin's disease and non-Hodgkin's lymphoma and its relationship disease activation.
  • The research reported in this paper was designed to study the role of plateled-derived growth factor (PDGF) in Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL).
  • The PDGF levels in 9 patients with HD and 12 NHL and in a control group consisting of 20 people, was measured by ELISA method.
  • The values of PDGF in the control group were 28.977+/-9 pg/ml, but were measured at 147.083+/-54 pg/ml in HD group and 131.487+/-56 pg/ml in NHL group (p < 0.01).
  • The observation of a 5-fold increase in PDGF values in the disease group when compared to the control group suggests that PDGF could itself be considered as a possible factor in the pathogenesis of HD and NHL.
  • [MeSH-major] Hodgkin Disease / etiology. Lymphoma, Non-Hodgkin / etiology. Platelet-Derived Growth Factor / analysis
  • [MeSH-minor] Adult. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Proteins / analysis. Risk Factors. Up-Regulation

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019446.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Platelet-Derived Growth Factor; 0 / platelet-derived growth factor A
  •  go-up   go-down


80. Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H, Morineau N, Jardel H, Moreau P, Gallazini-Crépin C, Gries P, Gressin R, Harousseau JL, Mohty M, Moreau P, Kraeber-Bodere F, Le Gouill S: Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging; 2010 Aug;37(9):1633-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.
  • PURPOSE: (18)F-fluorodeoxyglucose (FDG) PET is a non-invasive imaging technique recommended for the management of both diffuse large B-cell and Hodgkin's lymphomas.
  • This retrospective study investigated the value of FDG PET for initial staging and its prognostic impact on patients with mantle cell lymphoma (MCL).
  • Disease status after chemotherapy completion was assessed according to the International Workshop Criteria (IWC) for non-Hodgkin's lymphoma (NHL) response and IWC+PET.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Mantle-Cell / diagnostic imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Nucl Med Commun. 2009 Oct;30(10):770-8 [19657307.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2385-7 [18077791.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Clin Lymphoma Myeloma. 2008 Jun;8(3):159-65 [18650179.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Dec;12(12):1270-6 [17162208.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1693-701 [18798104.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2271-8 [16332971.001]
  • [Cites] Br J Haematol. 2006 Apr;133(1):43-9 [16512827.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):750-62 [17891190.001]
  • [Cites] Cancer. 2008 Aug 15;113(4):791-8 [18615506.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4365-70 [19652064.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2583; author reply 2583-4 [18779406.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1785-91 [11681422.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):567-75 [9452276.001]
  • [Cites] J Hematop. 2009 Jul;2(2):103-11 [19669190.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):29-38 [16173960.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4643-51 [15837966.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):329-36 [9640217.001]
  • [Cites] Blood. 2008 Jan 15;111(2):558-65 [17962512.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):401-8 [11818206.001]
  • [Cites] J Nucl Med. 2006 Aug;47(8):1267-73 [16883004.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):511-8 [19075279.001]
  • [Cites] Haematologica. 2008 Mar;93(3):471-2 [18310543.001]
  • (PMID = 20428863.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


81. Dzietczenia J, Wróbel T, Mazur G, Poreba R, Jaźwiec B, Kuliczkowski K: Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma. Med Oncol; 2010 Sep;27(3):743-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
  • Rituximab is an anti-CD20 humanized monoclonal antibody widely used in the treatment of B-cell non-Hodgkin's lymphomas (NHLs).
  • [MeSH-major] Antigens, CD46 / blood. Antigens, CD55 / blood. Antigens, CD59 / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm / genetics. Lymphoma, Follicular / immunology. Lymphoma, Large B-Cell, Diffuse / immunology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Complement Activation. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Monitoring. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Rituximab. Tumor Burden. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] Lab Invest. 2000 Mar;80(3):335-44 [10744069.001]
  • [Cites] Biochem Soc Trans. 1997 May;25(2):705-8 [9191187.001]
  • [Cites] Immunol Lett. 2007 Jul 31;111(1):6-13 [17572509.001]
  • [Cites] Eur J Haematol. 2000 Jan;64(1):3-9 [10680700.001]
  • [Cites] Cancer Immunol Immunother. 2003 Oct;52(10):638-42 [12811528.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3383-9 [11719378.001]
  • [Cites] Mol Immunol. 1999 Sep-Oct;36(13-14):929-39 [10698347.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1352-7 [11520782.001]
  • [Cites] Eur J Immunol. 2005 Jul;35(7):2175-83 [15971270.001]
  • [Cites] Leuk Res. 2006 May;30(5):625-31 [16289746.001]
  • [Cites] Trends Immunol. 2004 Sep;25(9):496-503 [15324743.001]
  • (PMID = 19662541.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD46; 0 / Antigens, CD55; 0 / Antigens, CD59; 0 / CD46 protein, human; 101754-01-2 / CD59 protein, human; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


82. Basu D, Yaranal PJ, Kalyan K, Soundararaghavan J: Mantle cell lymphoma--a clinicopathological study of 13 cases. Malays J Pathol; 2005 Jun;27(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mantle cell lymphoma--a clinicopathological study of 13 cases.
  • Mantle cell lymphoma is an uncommon non-Hodgkin's lymphoma.
  • In a period of four years, 13 cases of mantle cell lymphoma were diagnosed in our department, comprising 3.1% of all non-Hodgkin's lymphoma diagnosed.
  • Despite certain morphological similarity to other low-grade lymphomas, mantle cell lymphoma has a characteristic appearance of its own.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / immunology. Biopsy, Needle. Bone Marrow Examination. Cyclin D1 / immunology. Female. Humans. Immunohistochemistry. Immunophenotyping. Lymph Node Excision / statistics & numerical data. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16676688.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Antigens, CD20; 136601-57-5 / Cyclin D1
  •  go-up   go-down


83. Chang KC, Huang GC, Jones D, Lin YH: Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res; 2007 Nov 15;13(22 Pt 1):6666-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphomas, accounts for 30% to 40% of all lymphoma cases.
  • [MeSH-major] Antigens, CD1 / analysis. Dendritic Cells / immunology. Lymphoma, Large B-Cell, Diffuse / diagnosis. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. HLA-DR Antigens / analysis. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2008 Apr 15;14(8):2514; author reply 2515-6 [18413849.001]
  • (PMID = 18006767.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / CD1a antigen; 0 / HLA-DR Antigens
  •  go-up   go-down


84. Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO): Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Eur J Haematol; 2008 Mar;80(3):227-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
  • OBJECTIVES: The role of high-dose therapy and autologous stem-cell transplantation (HDT/ASCT) in the up-front treatment of poor-risk aggressive lymphoma is still unknown.
  • PATIENTS AND METHODS: Eighty-six patients with newly diagnosed and Ga-67 avid aggressive B-cell lymphoma received MegaCHOP for three courses and were evaluated for response by CT and Ga67S.
  • CONCLUSIONS: This response-adapted strategy including early treatment modifications prior HDT/ASCT have yielded encouraging PFS and OS in patients with poor-risk B aggressive non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Carmustine / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Melphalan / administration & dosage. Middle Aged. Podophyllotoxin / administration & dosage. Prednisone / administration & dosage. Prognosis. Prospective Studies. Risk Assessment. Survival Analysis. Transplantation, Autologous. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PODOFILOX .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088400.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; BEAM protocol; CHOP protocol
  •  go-up   go-down


85. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW: Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant; 2006 Sep;12(9):965-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
  • High-dose chemotherapy followed by blood or marrow transplantation (BMT) is generally considered the best salvage option for patients with relapsed diffuse large-B-cell non-Hodgkin's lymphoma (DLCL).
  • Mortality from lymphoma was 26.6% in allo-BMT recipients and 43.5% in auto-BMT recipients (P = .02).
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Transplantation. Disease-Free Survival. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920563.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Gil L, Styczynski J, Komarnicki M: Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection; 2007 Dec;35(6):421-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: A total number of 314 patients diagnosed for Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), multiple myeloma (MM) or acute lymphoblastic leukemia (ALL) were included in the study.
  • [MeSH-minor] Adolescent. Adult. Aged. Bacteria / drug effects. Bacteria / isolation & purification. Female. Fever of Unknown Origin. Humans. Leukemia / complications. Leukemia / therapy. Lymphoma / complications. Lymphoma / therapy. Male. Middle Aged. Neutropenia / complications. Neutropenia / diagnosis. Neutropenia / mortality. Prospective Studies. Risk Factors. Transplantation, Autologous / adverse effects. Treatment Outcome


87. Sánchez-Espiridión B, Sánchez-Aguilera A, Montalbán C, Martin C, Martinez R, González-Carrero J, Poderos C, Bellas C, Fresno MF, Morante C, Mestre MJ, Mendez M, Mazorra F, Conde E, Castaño A, Sánchez-Godoy P, Tomas JF, Morente MM, Piris MA, García JF, Spanish Hodgkin's Lymphoma Study Group: A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples. Clin Cancer Res; 2009 Feb 15;15(4):1367-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples.
  • PURPOSE: Despite major advances in the treatment of classic Hodgkin's lymphoma (cHL), approximately 30% of patients in advanced stages may eventually die as result of the disease, and current methods to predict prognosis are rather unreliable.
  • Gene-Set Enrichment Analysis was used to identify functional pathways associated with unfavorable outcome that were significantly enriched in either the Hodgkin's and Reed-Sternberg cells (regulation of the G2-M checkpoint, chaperones, histone modification, and signaling pathways) or the reactive cell microenvironment (mainly represented by specific T-cell populations and macrophage activation markers).
  • [MeSH-major] Gene Expression Profiling. Hodgkin Disease / therapy. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Paraffin Embedding. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19228737.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Dominguez P; Jara C; Mestre MJ; Quiben R; Mendez M; Borbolla L; Martinez MA; Grande C; Garcia-Cosio M; Montalban C; Garcia-Larana J; Bellas C; Provencio M; Castano A; Sanchez-Godoy P; Martin C; Martinez R; Menarguez J; Sabin P; Flores E; Gonzalez-Carrero J; Ponderos C; Alvaro T; Font L; Romagosa V; Fernandez de Sevilla A; Mollejo M; Cruz MA; Alvarez-Arguelles H; Llanos M; Morante C; Mazorra F; Conde E; Fresno MF; Rayon C; Nicolas C; Flores T; Garca-Sanz R; Guma J; Gonzalvo P; Fernandez G; Forteza J; Fraga M; Bello JL; Mendez JR; Garcia JF; Morente MM; Piris MA
  •  go-up   go-down


88. Jang G, Ko OB, Kim S, Lee DH, Huh J, Suh C: Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma. Transfusion; 2008 Apr;48(4):640-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
  • STUDY DESIGN AND METHODS: A prospective, randomized study was performed with 40 patients (14 with non-Hodgkin's lymphoma, 26 with multiple myeloma) undergoing ASCT.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / therapy. Multiple Myeloma / therapy
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / therapeutic use. Adolescent. Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prospective Studies. Recombinant Proteins / administration & dosage. Recombinant Proteins / therapeutic use. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194384.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6WS4C399GB / lenograstim
  •  go-up   go-down


89. Sansonno D, Tucci FA, Lauletta G, De Re V, Montrone M, Troiani L, Sansonno L, Dammacco F: Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia. Clin Exp Immunol; 2007 Feb;147(2):241-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HCV replicating form in lymphoid cells was associated strictly with mixed cryoglobulinaemia (MCG), in that it was found in six of 13 (46%) MCG patients, including two with B cell non-Hodgkin's lymphoma (NHL).
  • No traces of HCV-negative strand RNA were found in four patients with acute hepatitis C, in 15 with chronic active hepatitis without extrahepatic disorders, in seven with monoclonal gammopathy of undetermined significance, and in seven with B-NHL without MCG.
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow Cells / virology. Female. Hepatitis C, Chronic / complications. Humans. Lymphoma, B-Cell / virology. Male. Middle Aged. RNA, Viral / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Virus Replication

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Viral Hepat. 2004 Jul;11(4):310-8 [15230853.001]
  • [Cites] Curr Top Microbiol Immunol. 2000;242:55-84 [10592656.001]
  • [Cites] Arch Virol. 1994;134(3-4):293-302 [7510473.001]
  • [Cites] Virology. 1994 Aug 1;202(2):606-14 [8030225.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1887-92 [7655017.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] J Virol. 1995 Dec;69(12):8079-83 [7494326.001]
  • [Cites] Clin Exp Immunol. 1996 Mar;103(3):414-21 [8608640.001]
  • [Cites] J Clin Invest. 1996 Feb 1;97(3):845-51 [8609243.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4638-45 [8977256.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3328-37 [9787170.001]
  • [Cites] J Hepatol. 2005 Apr;42(4):491-8 [15763335.001]
  • [Cites] Science. 2005 Jul 22;309(5734):623-6 [15947137.001]
  • [Cites] J Virol. 2000 May;74(10):4824-30 [10775621.001]
  • [Cites] Hepatology. 2000 Aug;32(2):382-7 [10915746.001]
  • [Cites] Adv Virus Res. 2000;55:231-69 [11050944.001]
  • [Cites] Eur J Clin Invest. 2001 Jul;31(7):628-38 [11454019.001]
  • [Cites] Cell. 2002 Mar 8;108(5):717-25 [11893341.001]
  • [Cites] EMBO J. 2002 Oct 1;21(19):5017-25 [12356718.001]
  • [Cites] Blood. 2003 Jan 1;101(1):52-7 [12393733.001]
  • [Cites] J Virol. 2003 Mar;77(5):3007-19 [12584326.001]
  • [Cites] J Exp Med. 2003 Mar 3;197(5):633-42 [12615904.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7271-6 [12761383.001]
  • [Cites] J Virol. 2003 Oct;77(19):10432-6 [12970428.001]
  • [Cites] Eur J Immunol. 2004 Jan;34(1):126-36 [14971038.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1019-27 [16231354.001]
  • [Cites] J Hepatol. 2006 Feb;44(2):436-9 [16360233.001]
  • [Cites] J Virol. 2006 Feb;80(4):1734-41 [16439530.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1107-16 [16618405.001]
  • [Cites] Clin Exp Immunol. 2006 Feb;143(2):288-96 [16412053.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12766-71 [10535997.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2451-5 [1848704.001]
  • (PMID = 17223964.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC1810461
  •  go-up   go-down


90. Qureshi A, Ali A, Riaz N, Pervez S: Primary non-hodgkin's lymphoma of bone: experience of a decade. Indian J Pathol Microbiol; 2010 Apr-Jun;53(2):267-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-hodgkin's lymphoma of bone: experience of a decade.
  • OBJECTIVE: To study the prevalence and characterization of primary non Hodgkin's lymphoma of bone in a major referral center of Pakistan.
  • METHODOLOGY: All cases of primary non Hodgkin's lymphoma of bone, diagnosed at a referral center in Pakistan from January 1998 to July 2008 have been included.
  • Patients with diagnosis of lymphoma at some other site prior to diagnosis in bone biopsy were excluded from the study.
  • RESULTS: Sixty cases of primary non Hodgkin's lymphoma of bone were received, with a male to female ratio of 7: 3 (42 males and 18 females).
  • Overall, 52/60 (86.6 %) patients were diagnosed with Diffuse large B-cell non-Hodgkin's lymphoma.
  • CONCLUSION: Diffuse large B-cell lymphoma is the commonest type of primary non Hodgkin's lymphoma of bone in the Pakistani population.
  • Primary non Hodgkin's lymphoma of bone appears to be more common in males.
  • Our results are comparable to international data with various studies also showing that diffuse large B cell non Hodgkin lymphoma is the commonest primary bone lymphoma.
  • However, primary Bone Lymphoma is more common in children and young adults.
  • [MeSH-major] Bone Neoplasms / epidemiology. Bone Neoplasms / pathology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Bone and Bones / pathology. Child. Child, Preschool. Female. Femur / pathology. Humans. Humerus / pathology. Infant. Infant, Newborn. Male. Middle Aged. Pakistan / epidemiology. Pelvic Bones / pathology. Prevalence. Risk Factors. Sex Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551530.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


91. Das DK: Nucleolar positivity for CD20: a diagnostic aid in neoplasms of T-cell lineage? Acta Cytol; 2005 Jul-Aug;49(4):365-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: During a period of 5 years (1998-2002), 125 lymphoma cases consisting of 78 non-Hodgkin's lymphoma (NHL), 38 Hodgkin's disease (HD) and 9 NHL/HD were diagnosed by fine needle aspiration (FNA) cytology.
  • In FNA smears of NHL, the 2 most commonly used antibodies for immunocytochemical staining were CD3 (29 cases) and CD20 (33 cases).
  • RESULTS: Of the 78 NHL cases, 33 stained for CD20.
  • Twenty-five were successfully stained; of these, 3, consisting of 2 lymphoblastic lymphomas and 1 large cell lymphoma, showed a positive reaction.
  • CD20 staining performed on 1 of these lymphoblastic lymphomas and the large cell lymphoma showed a diffuse cytoplasmic reaction, respectively, in 2% and 0% only but positive staining of the nucleoli in 96% and 84% of cells, respectively.
  • Another lymphoblastic lymphoma case, which did not have an adequate number of CD3-positive cells to label it as of T-cell lineage also showed CD20 positive nucleoli in 60% of cells and a diffuse cytoplasmic reaction for CD 20 in 5% of cells.
  • [MeSH-major] Antigens, CD20 / metabolism. Hodgkin Disease / pathology. Lymphoma, Non-Hodgkin / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Antigens, CD3 / metabolism. Biopsy, Fine-Needle. Cell Lineage. Cell Nucleolus / metabolism. Cell Nucleolus / pathology. Child. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16124163.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


92. Adoga AA, Silas OA, Nimkur LT: Clinicopathological profile of malignant tumors of the oropharynx: a case series. East Afr J Public Health; 2010 Sep;7(3):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three (50%) patients had histologic diagnosis of non-Hodgkin's lymphoma (centroblastic), 1 had lymphoepithelioma and 2 had squamous cell carcinoma.
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Hospitals, University. Humans. Male. Middle Aged. Neoplasms. Nigeria. Prognosis. Retrospective Studies. Sex Distribution. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21516955.001).
  • [ISSN] 0856-8960
  • [Journal-full-title] East African journal of public health
  • [ISO-abbreviation] East Afr J Public Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tanzania
  •  go-up   go-down


93. Lin PC, Poh SB, Lee MY, Hsiao LT, Chen PM, Chiou TJ: Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol; 2005 May;81(4):349-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient with non-Hodgkin's lymphoma completed 6 courses of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisone) and autologous peripheral blood SCT (PBSCT).
  • [MeSH-minor] Acute Disease. Adult. Fatal Outcome. Female. Humans. Leukemia, Myeloid / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Male


94. Papaxoinis G, Fountzilas G, Rontogianni D, Dimopoulos MA, Pavlidis N, Tsatalas C, Pectasides D, Xiros N, Economopoulos T: Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol; 2008 Apr;19(4):780-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG).
  • BACKGROUND: The aim was to examine characteristics and treatment results of patients with mucosa-associated lymphoid tissue (MALT) non-Hodgkin's lymphomas.
  • PATIENTS AND METHODS: Epidemiological and clinical features of 97 patients with MALT lymphoma from the Hellenic Cooperative Oncology Group registry were analysed retrospectively for their prognostic significance in progression-free survival (PFS) and overall survival (OS).
  • Comparisons were made between patients with gastric and nongastric sites of primary lymphoma and between different therapeutic modalities.
  • Surgery did not offer survival benefit compared with chemotherapy in localised gastric lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156143.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


95. Yao B, Li YX, Fang H, Jin J, Liu XF, Yu ZH: [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases]. Ai Zheng; 2006 Apr;25(4):465-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
  • BACKGROUND & OBJECTIVE: The prognosis of primary non-Hodgkin's lymphoma (NHL) of the nasal cavity was poor, and the distant metastasis and local relapse rates are high.
  • METHODS: Clinical data of 129 patients with pathologically confirmed nasal NHL, treated from Jan.
  • Of the 129 patients, 116 were diagnosed as nasal NK/T-cell lymphoma.
  • CONCLUSIONS: CR rate after treatment is an important prognostic factor of nasal NHL.
  • Distant metastasis is the main failure pattern of nasal NHL.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / therapy. Lymphoma, Non-Hodgkin / therapy. Nasal Cavity. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell / therapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Remission Induction. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613682.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


96. Diepstra A, Poppema S, Boot M, Visser L, Nolte IM, Niens M, Te Meerman GJ, van den Berg A: HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens; 2008 Mar;71(3):219-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma.
  • Classical Hodgkin's lymphoma (cHL) is characterized by the presence of an abundant reactive infiltrate, lacking effective cytotoxic responses.
  • Especially in Epstein-Barr virus (EBV)-negative cHL, the neoplastic Hodgkin-Reed-Sternberg (HRS) cells have lost protein expression of major histocompatibility complex (MHC) class I, enabling escape from cytotoxic T lymphocyte (CTL) responses.
  • [MeSH-major] HLA Antigens / metabolism. Histocompatibility Antigens Class I / metabolism. Hodgkin Disease / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Alleles. Child. Female. Genetic Markers. Genotype. HLA-A Antigens / genetics. HLA-G Antigens. Herpesvirus 4, Human / isolation & purification. Humans. Immunohistochemistry. Male. Middle Aged. Reed-Sternberg Cells / immunology. Reed-Sternberg Cells / virology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18257895.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / HLA Antigens; 0 / HLA-A Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


97. Baijal G, Vadiraja BM, Fernandes DJ, Vidyasagar MS: Diffuse large B-cell lymphoma of the uterine cervix: a rare case managed novelly. J Cancer Res Ther; 2009 Apr-Jun;5(2):140-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma of the uterine cervix: a rare case managed novelly.
  • Non-Hodgkin's lymphoma (NHL) of the uterine cervix is exceedingly rare.
  • A biopsy revealed it to be a CD20-positive diffuse large B-cell (DLBCL)-type NHL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542675.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


98. Song Y, Cao Z, Li L, Zhang HT, Zhang X: Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and their interrelation. Chin J Cancer; 2010 Sep;29(9):781-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and their interrelation.
  • BACKGROUND AND OBJECTIVE: Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma (NHL), is heterogeneous on molecular and clinical levels, therefore, its prognosis is difficult to predict.
  • Using the Hans classification based upon the expression of CD10, Bcl-6, and MUM1, 54 patients had germinal center B-cell (GCB) phenotype and 82 had non-GCB phenotype.
  • The 5-year OS rate was 75% in the GCB group and 52% in the non-GCB group (P = 0.020).
  • The positive rate of Blimp-1 was 22.2% in the GCB group and 31.7% in the non-GCB group (P = 0.329).
  • CONCLUSIONS: The patients with GCB subtype of DLBCL had better prognosis than the non-GCB subtype.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. DNA-Binding Proteins / metabolism. Female. Follow-Up Studies. Humans. Immunophenotyping. Interferon Regulatory Factors / metabolism. Male. Middle Aged. Neprilysin / metabolism. Prognosis. Proportional Hazards Models. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20800019.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Repressor Proteins; 0 / interferon regulatory factor-4; 138415-26-6 / PRDM1 protein, human; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


99. Liu J, Song B, Wang Z, Song X, Shi Y, Zheng J, Han J: DNA repair gene XRCC1 polymorphisms and non-Hodgkin lymphoma risk in a Chinese population. Cancer Genet Cytogenet; 2009 Jun;191(2):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA repair gene XRCC1 polymorphisms and non-Hodgkin lymphoma risk in a Chinese population.
  • This hospital-based case-control study examined whether polymorphism in the DNA repair gene x-ray repair cross-complementing groups 1 (XRCC1 Arg194Trp [C-->T], Arg280His [G-->A], and Arg399Gln [G-->A]) played a role in susceptibility to non-Hodgkin's lymphoma (NHL) in the Chinese population.
  • We genotyped these polymorphisms for 221 histopathologically confirmed NHL cases and 254 age- and sex-matched healthy control cases in China.
  • No studied polymorphism alone was shown to be related to the risk of NHL or each histologic subtype of NHL.
  • When stratified by smoking status, however, the XRCC1Arg399Gln variant genotypes (homozygotes and heterozygotes) were associated with a 3.0-fold risk of follicular lymphoma among heavy smokers (95% confidence interval: 1.16-7.82; P = 0.02).
  • Further large-scale studies would confirm this association and clarify marginally significant trends in XRCC1 polymorphism combinations for an increased risk for NHL.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. DNA Repair / genetics. DNA-Binding Proteins / genetics. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. China / epidemiology. DNA / genetics. DNA / isolation & purification. DNA Primers. Exons / genetics. Female. Heterozygote Detection. Homozygote. Humans. Male. Middle Aged. Polymorphism, Single Nucleotide / genetics. Risk Factors. Smoking / genetics. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19446740.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; 9007-49-2 / DNA
  •  go-up   go-down


100. Omoti AE, Omoti CE: Sudden onset of herpes zoster following chemotherapy for orbital lymphoma in a HIV positive patient. Saudi Med J; 2007 Jan;28(1):125-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sudden onset of herpes zoster following chemotherapy for orbital lymphoma in a HIV positive patient.
  • We report a 38-year-old HIV positive female, who developed an acute attack of herpes zoster HZ involving the mandibular, C2, C3, C4, T1, and T2 dermatomes, 9 days after the commencement of the first cycle of chemotherapy regimen for non-Hodgkin's lymphoma NHL.
  • She had developed NHL of the ovary approximately 6 months earlier, followed by metastasis to the left orbit resulting in proptosis of the left eye.
  • A combination of a positive HIV status, lymphoma, and chemotherapy can predispose a patient to an attack of HZ involving many dermatomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Seropositivity / drug therapy. Herpes Zoster / etiology. Lymphoma, Non-Hodgkin / drug therapy. Orbital Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Prednisone / therapeutic use. Vincristine / therapeutic use






Advertisement